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In men, low testosterone is associated with an increased risk of all-cause and 
cardiovascular related mortality, and although its immunomodulatory properties have been well 
characterized, the impact of testosterone on both the severity of viral infection and the efficacy 
of vaccination remain poorly understood. The severity of influenza increases with age in men, 
and as circulating testosterone concentrations also decline with age in men, I hypothesized that 
reduced testosterone contributes to age-associated increases in influenza severity. A murine 
model was used, and consistent with in humans, young male mice had greater testosterone 
concentrations than did aged males. Following IAV infection, aged male mice experienced 
greater disease severity, mortality, and pulmonary inflammation than young males, while 
control of viral replication was delayed. Removal of testosterone in young males increased 
disease severity, and pulmonary inflammation independent of changes in viral replication. 
Because testosterone in young male mice reduced pulmonary inflammation, I further 
hypothesized that testosterone was altering the immune response to IAV infection. 
Testosterone reduced IAV severity not by changing pulmonary cytokine activity, but instead by 
accelerating pulmonary leukocyte contraction. To identify which immune cell types were 
persisting in testosterone-depleted males, we further characterized the composition of 
pulmonary cellular infiltrates. Testosterone depletion accelerated the contraction of IAV-specific 
CD8+ T cells, while inhibiting the influx of eosinophils into the lungs following clearance of virus 
from the lungs. The effects of testosterone on IAV-specific CD8+ T cells were mediated androgen 
receptor signaling and dependent on the environment in which they reside. In contrast with IAV 
infection where the immune suppressive effects of testosterone are protective, in the context of 
vaccination any reduction in immune response may be detrimental. Adult females tend to 
develop greater adaptive immune responses than males following vaccination in both preclinical 
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animal studies and human clinical trials. Following vaccination with irradiated transgenic P. 
berghei sporozoites expressing the P. falciparum CSP protein, adult female mice mounted 
greater adaptive immune responses and were better protected against challenge than adult 
males. No sex differences in adaptive immune responses or protection were observed in mice 
vaccinated prior to puberty, suggesting a role for sex steroid hormones. Depletion of 
testosterone in males increased, whereas rescue of testosterone decreased, adaptive immune 
responses and protection in males following parasite challenge. Taken together, these data 
suggest that testosterone confers protection during IAV infection by modulating the immune 
response, while testosterone concentrations in males reduce adaptive immunity and 
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Introduction to testosterone 
In addition to its better-known role as the primary male sex hormone, testosterone has 
been shown to have profound effects on a wide range of biological processes and influence 
states of health and disease in both sexes [1-3]. Testosterone along with dihydrotestosterone 
(DHT), androstenedione, and dehydroepiandrosterone (DHEA) comprise the androgen family of 
steroid hormones [4]. Of these four, testosterone is considered the dominant androgen and is 
found at the highest concentration in the circulation [5]. Though of higher potency, DHT is found 
at significantly lower concentrations and is irreversible converted from testosterone by the 
enzyme 5 α-reductase, with the liver being the primary site of testosterone’s conversion to DHT 
[4-7]. Both DHEA and androstenedione are produced by the adrenal gland and exert 1/10 and 
1/20 the androgenic effects of testosterone respectively [6, 8]. Though both can be converted to 
testosterone, the effects of this process on circulating testosterone concentrations is minimal [6, 
8]. Of the androgens, only DHT is unable to be converted to estrogen, thus simplifying the 
interpretation of DHTs effects on biological processes [4-6].  
In males, testosterone is primarily produced by the Leydig cells of the testes under the 
control of the hypothalamic-pituitary-gonadal axis (HPG) [8-10]. With the HPG axis, the 
hypothalamus first releases gonadotropin-releasing hormone (GnRH) in a pulsatile fashion 
which stimulates the release of follicle stimulating hormone (FSH) and luteinizing hormone (LH) 
into the circulation from the anterior pituitary gland [8, 9]. LH stimulates the Leydig cells of the 
testes to produce testosterone from cholesterol, while FSH acts on the Sertoli cells of the testes 
to stimulate spermatogenesis in the presence of testosterone [8, 9]. The production of 
testosterone is regulated by negative feedback, with high levels of testosterone resulting in the 
suppression of LH and GnRH secretion [8, 9]. Testosterone production by the Leydig cells results 
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in a relatively high concentration of testosterone in the testes which is then released into the 
periphery, yielding lower tissue concentrations of testosterone [8]. 
In the male periphery, only 2% of testosterone is typically found in an unbound state, 
30% is bound at high affinity to sex-hormone-binding globulin (SHBG), and the remainder is 
bound at relatively low affinity by non-specific proteins including albumin [6, 8, 11]. Free 
testosterone refers to the fraction of testosterone unbound to plasma proteins, while 
bioavailable testosterone refers to fraction of circulating testosterone that is either unbound or 
bound at low affinity by albumin and is thus able to readily dissociate in the tissues [8, 12]. It is 
this free state of testosterone that is believed to the biologically active form of testosterone [13, 
14]. Total testosterone refers to both the unbound and bound fractions of testosterone [8, 12]. 
In humans, both albumin and SHBG play important roles in regulating the bioactivity, 
metabolism, transport, and tissue specific localization of testosterone, with SHBG being shown 
to inhibit androgen bioactivity in vivo and in vitro  [12-14]. Whether SHBG is similarly involved in 
the regulation of androgens in adult rodents is unclear. Though hepatic expression of SHBG has 
been detected in fetal rats, only trace amounts have been detected in the serum of adult rats 
and mice [15, 16]. 
Most biological activities of testosterone and the other androgens are entirely mediated 
through the actions of the androgen receptor (AR) through a variety of mechanisms [2, 5, 17-
19]. The AR is a member of the nuclear receptor superfamily and is encoded on the X 
chromosome [2, 17, 20]. In the canonical or genomic pathway of androgen receptor activation, 
the AR functions as a ligand-dependent nuclear transcription factor [2, 17, 18]. In the absence of 
ligand (e.g., testosterone or DHT), the AR typically resides in the cellular cytoplasm in association 
with heat shock proteins (HSP) including HSP90, HSP70, and p23 [2, 17, 18, 21]. Androgens can 
freely diffuse through the plasma membrane and binding to the AR induces a conformational 
4 
 
change, resulting in heat shock protein dissociation, nuclear translocation, and the dimerization 
of the AR [18]. Once in the nucleus, co-activators are recruited, and the dimerized AR-ligand 
complex recognizes and binds to specific DNA sequences known as androgen response 
elements. Following ARE binding, the entire complex then functions to regulate the transcription 
of androgen-responsive genes [17, 18]. In addition to this genomic pathway, the AR is also able 
to activate non-genomic signaling pathways, which are characterized by rapid androgenic 
responses resulting in cellular changes without the need to first alter transcription and 
translation of androgen responsive genes [18]. The non-genomic AR signaling pathways are 
generally considered to originate at either the plasma membrane or the cytoplasm and can 
result in the release of intracellular calcium or the activation of protein kinases including 
mitogen-activated protein kinase, protein kinases A, B, and C [18, 19, 22]. Cellular expression of 
AR generally considered to be needed for direct androgenic effects on cells, and genetic models 
have demonstrated widespread mammalian AR expression throughout a variety of cell and 
tissue types including those of immune system [17, 23, 24]. 
 
Testosterone deficiency and androgen replacement therapy 
In males, after an initial surge during fetal development, testosterone concentrations 
remain low and then rapidly increase with the onset of puberty [25]. In normal males, 
testosterone production peaks at roughly 20-30 years of age and thereafter gradually declines 
with progressing age, with clinically low testosterone levels observed in 19% of men in their 60’s 
increasing to 49% of men in their eighties [26-28]. By the year 2025, as many as 6.5 million 
American males 30-79 years of age are projected to meet the clinical definition of symptomatic 
testosterone deficiency [29]. The reasons for age-related declines in androgenic function are 
believed to involve decreased Leydig cell responsive to LH stimulation leading to a reduction in 
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total testosterone production [30, 31], as well as age-associated increases in SHBG [32-34]. In 
addition to age related declines in testosterone, genetic conditions (e.g., Klinefelter’s syndrome 
and congenital gonadotropin deficiency), medically induced hypogonadism, and tissue damage 
from infection (e.g., mumps associated orchitis) or trauma can result in low testosterone 
concentrations in otherwise reproductively aged males [9]. 
In addition to its it’s well know role as the primary males sex hormone, testosterone can 
have profound effects on systemic health and disease and has been demonstrated to modulate 
the functions and activities of a variety of tissue and cell types [35]. For example, in addition to 
regulating sperm production and secondary male sex-characteristics, testosterone has also been 
shown to influence metabolic function, cardiovascular function, promote bone mineral density, 
and alter the functions of the immune system [25, 36-39]. Consistent with these observations, 
men with low testosterone, whether congenital, acquired, or age-related, are at an increased 
risk of all-cause and cardiovascular related mortality [35, 40-43]. Additionally, low testosterone 
in adult males has been associated with metabolic dysfunction, osteoporosis, muscle weakness, 
fatigue, cognitive impairment, and sexual dysfunction; while in hypogonadal men, testosterone 
replacement therapy has been shown to improve cardiovascular disease outcomes, increase 
quality of life perceptions, and improve age-associated anemia [41, 44-48].  
Although safety concerns exist (e.g., cardiovascular disease risk) [49, 50], the perceived 
consequences of low testosterone combined with the potential benefits of testosterone 
replacement therapy have resulted in a dramatic increase in its therapeutic use over the last 
two decades [49-52]. As of 2013, an estimated 2.3 million men were undergoing testosterone 
replacement therapy in the United States alone in 2013, representing 1.67% of the insured male 
population aged 30 and older, with the highest frequency of usage occurring in men 40-64 years 
of age [49, 50]. Included in these numbers is a 4-fold increase in testosterone replacement 
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therapy use in reproductively aged males (i.e. 18 to 45 years of age), a demographic often 
overlooked in studies of the implications of low testosterone [53]. However, despite the 
increasing popularity of testosterone replacement therapy, little remains known of the influence 
of testosterone deficiency and testosterone replacement therapy on the outcomes of infection 
and vaccination. 
 
The immunomodulatory effects of testosterone 
Testosterone and DHT have been shown to be broadly immunomodulatory and capable 
of significantly altering the cellular functions of both innate and adaptive immune cells, either 
through direct AR signaling in target cells, or indirectly through interactions with other cells 
types or the environment in which they reside [5, 23, 54-57]. Furthermore, developmental stage 
specific AR expression and androgenic effects have been described for immune cells, 
complicating the interpretation of androgenic effects on the immune system [54, 58, 59]. When 
acting on the immune response, testosterone in generally considered to be immunosuppressive 
[23], and the known effects of testosterone on the major cell populations of the immune system 
are summarized below.   
Both human and murine neutrophils have been shown to express functional ARs [24, 
60], with the numbers of mature neutrophils and the proliferative potential of bone-marrow 
derived neutrophil precursors being reduced in AR KO mice [60]. In both mice and in humans, 
testosterone treatment has been shown to promote tissue recruitment and accumulation of 
neutrophils while altering their functional activities [61, 62]. For example, testosterone is 
associated with reduced neutrophil expression of proinflammatory mediators including 
decreased expression of CD11b, reduced production of reactive oxygen species, and reduced 
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leukotriene biosynthesis, while testosterone promotes expression of anti-inflammatory 
mediators including IL-10 and TGFβ [61, 62]. 
As with neutrophils, both human and murine macrophages populations have been 
shown to widely express functional ARs, with testosterone having been shown to broadly alter 
the biological activities of these cells [24, 63-66]. In both mice and humans, testosterone and AR 
signaling in macrophages has been shown to suppress the production of proinflammatory 
mediators (e.g., nitric oxide,  IL-β, IL-6, and TNFα) while promoting the production of IL-10 [67-
70]. In murine models of allergic lung inflammation, AR signaling in males promotes M2 
macrophage polarization, while the expression of the eosinophil recruiting chemokines Ccl11 
and Ccl24, were reduced in AR-deficient murine alveolar macrophages [71]. Gonadectomy of 
male mice increased macrophage expression of TLR4 [72], while reducing the number of splenic 
macrophages in Balb/C mice [73]. Testosterone has also been shown to inhibit apoptosis of 
bone-marrow derived macrophages of Leishmania donovani infected female mice [74]. 
Moreover, both testosterone and DHT treatment have been shown to reduce Fcγ receptor 
expression by splenic macrophages in guinea pig models of Leishmania infection [75].  
Dendritic cells (DCs) are a diverse pool of professional antigen presenting cells that 
canonically play roles in immune surveillance, cytokine production, and the activation and 
orchestration of T cell responses [76-78]. Two predominant DC subsets have been identified: 
conventional dendritic cells (cDCs) which typically specialize in immune surveillance and antigen 
presentation to T cells, and plasmacytoid dendritic cells (pDCs) which are characterized by a 
reduced capacity for antigen presentation while being the dominate source of both type 1 and 
type 3 interferons following viral infection [23, 76, 77, 79]. Despite, the lack of reported 
androgen receptor expression by both pDCs and cDCs, androgenic effects on DC populations 
have been observed in studies of both humans and in mice [54]. In castrated mice, depletion of 
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testosterone has been shown to promote cDC maturation and increase costimulatory molecule 
(e.g., MHCII, CD80, and CD83, CD86, and OX-40L) expression [80]. cDCs in the peripheral blood 
of hypogonadal men show increased activation following TLR9 signaling with expression of the 
activation and degranulation marker CD107b being inversely correlated with serum 
testosterone concentration [81]. Furthermore, clinical studies have demonstrated reduced pro-
inflammatory cytokine production (e.g., IL-1β, IL-6, and TNFα) by cDCs following testosterone 
treatment [79]. Treatment of human pDCs with DHT significantly reduced IFNα production 
following TLR7 activation [82]. Given the lack of functional AR expression by dendritic cells, the 
mechanisms mediating these androgenic effects are currently remain unknown.  
Like DCs, eosinophils have been shown to be androgen-responsive despite the absence 
of functional androgen receptor expression [24, 54, 83]. In murine models of  Brugia pahangi 
infection, testosterone has been shown to suppress eosinophilic responses to infection [84], 
while testosterone treatment decreases peripheral eosinophil counts in both castrated male and 
female guinea pigs [85, 86]. Furthermore, testosterone has been shown to reduce eosinophilic 
adhesion to human mucosal microvascular endothelial cells in the nasal mucosa and reduce 
tissue specific eosinophilic viability [87]. In mice, testosterone-mediated differences in 
eosinophilic responses have been attributed to the actions of Type II innate lymphoid cells 
(ILC2s), with AR signaling inhibiting the differentiation of ILC2 progenitor cells into mature ILC2s 
[88, 89]. Treatment of mice with DHT reduces ILC2 numbers and reduces the production of IL-5 
needed for eosinophilic responses to airway inflammation [89].  
The effects of testosterone and AR signaling on other innate immune cell populations 
are less well characterized. Testosterone treatment of murine natural killer (NK) cells results in 
reduced cytotoxic activity [90], while medical castration of human males increases the 
percentage of NK cells isolated from PBMCs relative to healthy controls [91]. Furthermore, 
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testosterone has been shown to reduce IL-6 production by monocytes isolated from human 
PBMCs [92, 93].  
Though the effects of female sex hormones on the biological activities of B cells are well 
established, the effects testosterone on these cell populations are less well understood [94]. 
Male patients with Klinefelter’s syndrome and idiopathic hypogonadotropic hypogonadism have 
elevated peripheral B cell counts relative to healthy controls, which are subsequently lowered 
following the initiation of androgen replacement therapy [95, 96]. In mice, bone marrow, 
splenic, and peripheral blood B cell populations expand following castration and are elevated in 
androgen insensitive Tfm mice [97-103]. In humans, higher testosterone concentrations are 
associated with reduced neutralizing antibody responses following vaccination with the trivalent 
inactivated seasonal influenza vaccine [104], while testosterone treatment of both total human 
PMBCs and purified B cells reduced total IgG and IgM antibody production in both systemic 
lupus erythematosus patients as well as in healthy controls [92, 93]. In neonatal 
gonadectomized rats infected with Seoul virus, treatment with DHT reduces anti-Seoul virus IgG 
and Th1 associated IgG2a antibody responses [105]. Despite the suppressive effects of 
testosterone on humoral immune responses, functional AR expression has not been consistently 
detected by mature peripheral B cell populations [5, 23, 59]. Instead, evidence suggests 
testosterone primarily regulates humoral immunity during lymphopoiesis prior to the acquiring 
of antigen specificity, with both immature B cell populations and bone marrow stromal cells 
having been shown to express functional ARs [5, 97, 103, 106]. Consistent with this idea, 
inhibition of AR signaling in osteoblast-lineage cells increase B cell lymphopoiesis in the bone 
marrow of male mice, while androgens have been shown to promote the apoptosis of immature 
B cells [94, 107]. However, one study has demonstrated that B cells isolated from the PBMCs of 
healthy donors not only expressed low levels of AR, but were also capable of metabolizing 
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androstenedione to testosterone via 17β-HSD expression and further capable of metabolizing 
testosterone to DHT via 5α-reductase in vitro [108]. Whether intracrine testosterone synthesis is 
biologically relevant process for lymphocytes, or an artifact of in vitro manipulation is unclear 
[109].  
Testosterone has also been shown to alter the function, differentiation, and fate of both 
CD4+ and CD8+ T cell populations. In hypogonadal men, the proportion of CD4+ T cells isolated 
from PBMCs is increased relative to healthy controls, while these numbers normalize following 
the initiation of testosterone replacement therapy [110]. In vitro, testosterone has been shown 
to arrest cell cycle progression and promote apoptosis in established T cell lines, while 
promoting Fas-dependent apoptosis of Coxsackie virus specific Th2 cells by decreasing Bcl2 
expression [111, 112]. In mice, androgen ablation has been shown to increase the numbers of 
both CD4+ and CD8+ T cells, while increasing their proliferative potential in response to 
stimulation [113]. In animal models of infection and inflammation, androgens have been shown 
suppress T cell recruitment and the production of IFNγ, IL-2, and IL-12 by T cells, while 
promoting the expression of Th2 and Th17 associated cytokines including IL-4, Il-5, and IL-17 
[114-121]. Moreover, in both humans and in animal models, testosterone has been shown to 
promote the expansion of regulatory T cell (Tregs) populations, while enhancing IL-10 
production and Foxp3 gene expression within these cells [114, 116, 118, 122-125]. In contrast 
with the generally anti-inflammatory effects of testosterone reported above, testosterone 
treatment of male mice infected with Coxsackievirus group B viruses enhances production of 
Th1 associated cytokines including IL-2 and IFNγ by splenic CD4+ T cells, while testosterone 
treatment of female mice suppresses Th2 associated production of IL-4 and IL-5 by splenic CD4+ 
T cells [126]. Whether, proinflammatory effects of testosterone in this model represents a 
difference in pathogen specific responses is unclear.  
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Despite the first paper showing a link between male castration and thymic enlargement 
being published in 1904 [127], the exact mechanisms by which testosterone alters the biological 
activities of T cells remains unclear. While some groups have failed to detect functional ARs in 
mature T cells isolated from mice, humans, and established T cell lines [97, 125, 128, 129], 
others have reported functional cytosolic AR expression and demonstrated functional genomic 
AR signaling in these cells [108, 123]. Furthermore, other groups have suggested that murine T 
cells only express membrane bound ARs with androgenic effects being mediated through non-
genomic calcium release [55, 116, 130-133]. The most convincing body of evidence supports a 
role for testosterone in regulating T cell selection and development in the thymus. As was first 
reported over 100 years ago, castration of mice results in enlargement of the thymus and 
increases thymic output, while testosterone replacement in castrated mice results in thymic 
regression and decreases the number of CD4+CD8+ double positive thymocytes [23, 127, 134, 
135]. Furthermore, androgens have been shown to both directly and indirectly lead to 
thymocyte apoptosis with thymic T cells being shown to express functional AR and exhibit 
classical AR signaling in response to androgen stimulation [97, 131, 136-138]. Moreover, both 
the cortical and medullary regions of the thymus express AR and respond to androgen 
treatment [97, 139, 140], with AR signaling in thymic epithelial cells being shown to increase 
positive selection of thymocytes [141, 142].  
 
The effects of testosterone on Infection and vaccination 
Despite the well-established body of literature showing profound immunomodulatory 
activities of testosterone, relatively little is known about the influence of testosterone on the 
outcomes of infection and vaccination. Moreover, though sex differences in infectious disease 
outcomes in have been well documented, and age-related changes in disease risk have been 
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postulated to be mediated by testosterone changes, surprisingly few human epidemiological 
studies have directly evaluated the role of testosterone as a variable mediating these 
differences [56, 143-148]. In those studies where androgen concentrations were considered, 
high testosterone concentrations have been correlated with the increased prevalence of human 
papilloma virus in men who have sex with men [149], while free testosterone concentrations in 
women, but not, men have been associated with throat colonization of Staphylococcus aureus 
[150]. In community-acquired pneumonia patients, testosterone concentration has been shown 
to be inversely correlated with the severity of pneumonia and organ failure risk [151], while 
hypogonadism due to Klinefelter’s syndrome is associated with increased pneumonia associated 
mortality [43]. Furthermore, low serum testosterone is associated with an increased risk of 
morbidity and frailty in males infected with human immunodeficiency virus (HIV) [152], as well 
as an increased risk of infection related hospitalization in male hemodialysis patients [153].  
Most direct evidence for a role in testosterone in altering the outcomes of infectious 
diseases comes from the use of animal models. In rodent models of amebic infection, 
testosterone concentrations correlate with the incidence of amebic liver abscesses, with 
testosterone increasing the severity of Entamoeba histolytica infection at least in part through 
inhibition of IFNγ production by natural killer T cells [114, 143, 154]. In mice infected with 
Babesia microti, testosterone is associated with increased parasitemia and anemia [155], while 
the severity of Toxoplasma gondii infection is reduced in female mice following testosterone 
treatment [156]. Following Leishmania major infection, male mice typically have greater hepatic 
parasite loads than females, with these differences being reversed through castration of males 
or testosterone treatment of females [157, 158]. In mice infected with Brugia pahangi, 
testosterone treatment of either castrated males or female mice, reduced resistance to 
13 
 
infection and suppressed intraperitoneal lymphocyte, macrophage, and eosinophilic responses 
[159].  
Moreover, these effects of testosterone are not limited to parasitic infections. In murine 
models of Mycobacterium marinum infection, skin lesion severity and the frequency of systemic 
bacterial dissemination is greater in male mice relative to females with these differences being 
reversed through testosterone depletion in males [160, 161]. Baseline testosterone 
concentrations have been correlated with viremia following experimental infection with 
Venezuelan equine encephalitis virus in macaques [162], while early work on the effects of 
testosterone on influenza A virus (IAV) infection in female swiss mice found that testosterone 
treatment increased viral loads and the rate of viral replication in the lungs [163]. In contrast, 
more recent work in lethal models of IAV infection, have shown that surgical testosterone 
depletion in male mice significantly increases morbidity and death, but does not alter either the 
magnitude or the kinetics of viral replication [164].   
As with infection, though sex differences in the outcome vaccination have been well 
described [57, 165, 166], only a handful of studies have evaluated the impacts of testosterone 
on the immune response to vaccination. Notably, in humans, elevated serum concentrations are 
associated with reduced neutralizing antibody responses to the trivalent inactivated influenza 
vaccine [104]. In HIV infected men who received the seasonal influenza vaccine, plasma 
testosterone concentrations have been shown to be inversely correlated with influenza-specific 
antibody avidity [167]. While, testosterone treatment of female mice suppresses protection 
following vaccination with the surface membranes of P. chabaudi infected red blood cells [168]. 
Finally, though testosterone replacement therapy in aged male macaques has been shown to 
reduce the decline in immune function, only modest improvements in antibody production 
following vaccinia virus vaccination were observed [169].  
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Taken together, these data suggest that, testosterone is highly immunomodulatory and 
can have profound influences on the outcomes of infection, inflammation, and vaccination. 
Whether these effects are beneficial or detrimental will likely be dependent on the nature of the 
immunological challenge. I hypothesize that testosterone will be protective in instances of 
infection where disease is largely mediated by the immune response to the pathogen (e.g., IAV), 




















Influenza A viruses 
Background 
Influenza viruses occupy four genera of the Orthomyxoviridae family and are classified 
as influenza A (IAV), B (IBV), C (ICV), or D (IDV) viruses based on antigenic variation of the 
nucleoprotein (NP) [170, 171]. All influenza viruses are enveloped and possess a segmented 
single stranded negative sense RNA genome, with IAV and IBV comprised of 8 segment 
genomes, while ICV and IDV are comprised of 7 segment genomes [172]. For IAV and IBV, the 
viral surface contains two primary glycoproteins, the hemagglutinin (HA) protein that facilitates 
viral entry via the sialic acid receptor (SA), and the neuraminidase protein (NA) that is involved 
in viral release [170], while for ICV and IDV, both functions are replaced by the single 
hemagglutinin-esterase-fusion protein [173]. The viral envelope also contains the ion channel 
forming matrix 2 protein (M2), while the matrix 1 protein (M1) forms a coat just under the viral 
envelope [172]. Inside this structure resides the viral ribonucleoprotein complexes (RNP) which 
are comprised of each of the genomic negative sense RNAs encapsulated in NP protein along 
with each of the three polymerase proteins (PA, PB1, and PB2) [172]. Influenza viruses also 
contain non-structural protein 1 (NS1), which functions as a viral virulence factor [174], and the 
nuclear export protein (NEP) which is primarily involved nuclear export of the viral RNP [175].    
Due to their increased diversity, IAV isolates are further classified into subtypes based 
on the antigenic properties of the HA and NA surface proteins, with 16 HA (H1-H16) and 9 NA 
(N1-N9) subsets being isolated to date from waterfowl [172]. An additional two HA (H17 and 
H18) and two NA (N10 and N11) subsets have isolated from bats, but these isolates do not 
appear to recognize sialic acid (SA) or be capable of reassortment with other IAV isolates [170, 
176]. Host specificity and tissue tropism is in part mediated by HA sialic acid binding 
preferences, with human isolates preferentially binding to α2,6 linked sialic acid residues, while 
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HA proteins of avian isolates preferentially bind to α2,3 linked sialic acid residues [170]. Because 
of the immense selective pressure placed by the immune system on the HA and NA proteins, 
antigenic drift (i.e., the gradual accumulation of mutations), continually yields new antigenic 
variants, which can be attributed to the error prone nature of the RNA-dependent RNA 
polymerase and the lack of proof-reading abilities by this structure [177]. Further IAV diversity 
results from less frequent antigenic shifts which are the result of genome reassortment 
following coinfection with dissimilar strains. This is more likely to occur in some species such as 
swine which express both avian and human receptor and can serve as mixing vessels, as was the 
cases with the 2009 pandemic strain which resulted from a triple reassortment [178]. 
Migratory waterfowl (order Anseriformes) and shorebirds (order Charadriformes) are 
the natural reservoir of influenza A viruses, with the virus being capable of infecting, and being 
transmitted, within numerous other species (e.g., domestic poultry, swine, seals, bats, dogs) 
including humans [170, 179, 180]. Though a cause of gastrointestinal infection within avian 
populations, influenza virus infection in mammals leads to mild to severe disease of the 
respiratory tract [170]. Cross-over of zoonotic IAV strains and subsequent adaptation to humans 
can result in emergence of worldwide influenza pandemics such as those seen with the 1918 
Spanish flu (H1N1), the 1957 Asian flu (H2N2), the 1968 Hong Kong flu (H3N1), and the 2009 
H1N1 pandemic strain [170, 178]. The most well-known of these pandemics was the 1918 
Spanish flu, which was estimated to have infected roughly one third of the world population 
killing an estimated 50 million people [178]. Though somewhat less dramatic than influenza 
pandemics, seasonal influenza transmission causes a significant global burden of disease. In the 
United States, annual seasonal influenza virus transmission results in an estimated 115,000 to 
630,000 hospitalizations and 5,000 to 17,000 deaths [181], while globally these numbers are 
estimated at 3 to 5 million cases of severe illness and roughly 500,000 deaths per year [170]. In 
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the Netherlands, influenza has been identified as the second leading cause of infection related 
disability-adjusted life year [182]. Influenza also has significant economic implications, with the 
direct and indirect economic cost associated with seasonal influenza estimated to be 11.2 billion 
dollars per year in the United States alone [183]. Currently, both the H1N1 and H3N2 subtypes, 
as well as two strains of IBV, circulate within the human population on a seasonal basis 
corresponding with the cold season in temperate climates, while seasonal forcing appears to be 
less defined in the tropics [170].  
 
Innate immune response to primary influenza A virus infection  
Influenza A viruses primarily infect and productively replicate in epithelial cells of the 
upper and lower respiratory tract [184-186], with these cells forming the first line of defense 
against influenza virus infection. In addition to physical and mechanical barrier functions (e.g., 
mucus production and ciliary action), these cells cell limit initial viral infection through the 
activation type I and type III IFN responses [187-190]. Infection of epithelial cells additionally 
results in the production of proinflammatory cytokines and chemokines that trigger the 
induction of the local and systemic inflammatory response. For example, early production of 
cytokines including IL-1, IL-6, and TNFα facilitate innate immune cell infiltration out of the 
circulatory system, while chemokines such as CXCL1 and CCL3 recruit neutrophils and 
macrophages to the site of infection [190].  
Tissue resident alveolar macrophages are typically found within the luminal spaces of 
the respiratory tract (e.g., alveoli, bronchi, and bronchioles) where they perform immune 
surveillance functions and help maintain lung homeostasis [191]. During IAV infection, these 
cells are typically the first immune cells to encounter virus and contribute to viral clearance 
through the phagocytosis of virally infected apoptotic cells, the production of inflammatory 
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mediators including TNFα, IL-1β, CXCL10 and INOS, and the direct inhibition of viral infection of 
alveolar epithelial cells [192-196]. Additionally, alveolar macrophages have been shown to be 
critical mediators of antibody-induced inflammation and antibody-dependent cellular 
phagocytosis following IAV Infection [197]. In the absence of alveolar macrophages, IAV 
infection results in the accumulation of cellular debris and the loss of respiratory function, 
suggesting that these cells may additionally play a role in the in resolution of disease [198]. This 
is further supported by observations that alveolar macrophages can be induced to express 
markers of a M2 immunoregulatory phenotype, including expression of IL-10 and hepatocyte 
growth factor [191, 199, 200]. Though other macrophage populations are recruited to the sites 
of IAV infection, including interstitial macrophages which typically reside in the lung 
parenchyma, their contribution to the control of infection remains under studied [191, 201, 
202]. 
Neutrophils are typically the earliest cell type to cross the vascular epithelium in 
appreciable numbers and localize in IAV infected tissues, where they contribute to the control of 
viral replication through the phagocytosis of apoptotic IAV infected cells, cytokine release, and 
the production of reactive oxygen species [54, 203]. Depletion of neutrophils in mice increases 
the severity of moderate to severe IAV infection, and leads to increased mortality, increased 
pulmonary viral load, viral dissemination to extrapulmonary tissues, and decreased lung 
function [204-207]. In addition to phagocytic functions, neutrophils play a critical role in the 
recruitment of CD8+ T cells to the sites of IAV infection at least in part through the deposition of 
the leukocyte chemoattractant CXCL12 [208]. Consistent with these observations, early 
depletion of neutrophils in murine models reduces the magnitude of CD8+ T cell infiltration and 
results in impaired CD8+ T cell activation [209]. As with other cell types, excessive or aberrant 
neutrophil responses can enhance disease following IAV infection. For example, in clinical cases 
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of IAV, the presence of high levels of neutrophil extracellular traps correlates with lung damage 
and is associated with poorer clinical outcomes, while the number of neutrophils in the lower 
respiratory tract has been correlated with severe outcomes following IAV infection [210, 211]  
Dendritic cells play several important roles in immunity to IAV infection and can be 
broadly divided into two categories: plasmacytoid dendritic cells (pDCs) and conventional 
dendritic cells (cDCs) (i.e., myeloid derived dendritic cells) [212, 213]. In addition to producing 
proinflammatory cytokines, DCs can be directly infected with IAV or otherwise traffic IAV 
peptide to the draining lymph nodes, where they present antigen to and prime CD4+ and CD8+ T 
cells more efficiently than macrophages populations [213, 214]. Following primed T cell 
migration to the respiratory tract, these cells further proliferate, differentiate, and develop 
effector phenotypes following further interactions with DC populations [213, 215]. Plasmacytoid 
dendritic cells require direct IAV infection to perform their APC and T cell support roles [216]. 
Protective IAV-specific CD8+ T cell responses require interactions with dendritic cells in the lungs 
to maintain CD8+ T cell populations (both pDCs and CD8a+ populations [215].  
The role of eosinophils in the immune response to IAV has been less well studied. 
Eosinophils are susceptible to IAV infection, and in murine models of asthma, activated 
eosinophils have been associated with increased numbers of CD8+ T cells in the airways. 
Furthermore, IAV virus or peptide-exposure alone is enough to induce eosinophilic 
degranulation and induce CD8+ T cell proliferation and activation [217]. Eosinophils can acquire 
and present IAV peptide [218]. Epithelial cells produce RANTES in response to IAV infection and 






Adaptive immune response to influenza A viruses 
The adaptive immune response to IAV consists of CD4+ and CD8+ T cell responses in 
addition to antibody production by B cells, with all three cell types playing critical roles in the 
efficient control of influenza virus infection [220]. Following IAV induced activation, CD4+ T cells 
can differentiate into several Th subsets that carry out diverse effector. CD4+ T cell 
differentiation in the presence of IL-6 and IL-21 leads to the development of T follicular helper 
cells (Tfh), which are involved in the development of B cell responses during influenza virus 
infection [221]. Differentiated Th1 cells produce IFN-γ, TNF-α and IL-2 and promote cytotoxic 
CD8+ T cell responses in addition to directly participating in the killing of virally infected cells via 
Fas/Fas-L mediated apoptosis and perforin/granzyme B dependent pathways [221-223]. In 
contrast, influenza virus infection has been shown to inhibit the development and recruitment 
of Th2 cells into the lungs (IFN-γ dependent) [224]. In addition to their more well characterized 
role in controlling the numbers and activities of diverse cell types [225], CD4+ regulatory T cells 
have been shown to play a critical role in tissue repair and following IAV infection [226], while 
also promoting the differentiation of Tfh cells [227].  
Upon primary IAV infection, CD8+ T cells are activated by APCs (e.g., macrophages and 
dendritic cells) in the lymphoid tissues, proliferate, and are then recruited to the sites of viral 
infection through chemokine-chemokine receptor dependent interactions [220, 228]. Once to 
the site of infection, CD8+ T cells continue to proliferate following interactions with dendritic 
cells [229]. , and control IAV through the production of antiviral cytokines (e.g., TNFα, MIP-1β 
and IFNγ), in addition to lysis of virally infected cells through the release of perforin and 
granzyme, the Fas-FasL pathway, and the TNF-related apoptosis inducing ligand (TRAIL) pathway 
[230-232]. CD8+ T cells play a critical, but non-essential role in the control of influenza virus 
infection. In their absence, control of viral replication can still occur through antibody-
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dependent mechanisms, but this is a slower less efficient process [170]. CD8+ T cells generally 
recognize internal more conserved viral epitopes (e.g., M1, NP, and polymerase proteins) and 
recent work supports a greater cross-reactive potential of CD8+ T cells relative to humoral 
responses [170, 223]. Following control of viral replication, most CD8+ T cells undergo apoptosis, 
while a few will go on to form a pool of memory cells [223].   
Antibody production by B cells is the primary mechanism for the prevention of IAV 
reinfection, but in the absence of a CD8+ T cell response, the humoral immune response has 
been shown to be sufficient to control primary IAV infection, albeit at a slower rate [170, 233, 
234]. The antibody responses to IAV primarily targets the HA and NA proteins, and the presence 
of antibodies recognizing these two proteins being correlating with protective immunity [220], 
while antibodies against M2 and NP have also being demonstrated [235]. HA-specific antibodies 
can inhibit viral attachment and entry and are thus capable of neutralizing viral activities [170, 
220, 233, 234]. In addition to viral neutralization, humoral immune responses also contribute to 
the control of IAV infection though antibody-dependent cellular cytotoxicity, antibody-induce 
inflammation, and antibody-dependent cellular phagocytosis dependent mechanisms [197, 233, 
234, 236-238]. Virus-specific IgG, IgM, and IgA antibodies have all been correlated with the 
resolution of primary IAV infection, or protection against secondary challenge [239-241].  
 
Animal models of influenza A viruses 
In order to expand our understanding of IAV immunology, pathogenesis, and host 
contributions to disease severity, several animal models of influenza virus infection have been 
developed, with mice being the most widely used [242, 243]. The preferential use of mice in the 
study of IAV, is in part due to their small size, low cost, ease of animal husbandry, and the wide 
availability of mouse-specific reagents [242, 243]. However, most human influenza strains do 
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not replicate efficiently in mice and require adaptation to achieve adequate viral replication, 
with A/Puerto Rico/8/1934 (H1N1; PR8), mouse adapted A/California/O4/09 (H1N1; ma2009), 
and A/WSN/33 (H1N1; WSN) being examples of commonly used mouse-adapted strains [180, 
242-244]. Disease following IAV infection in mice typically presents with hypothermia, weight 
loss, hunching, lethargy, ruffled fur, and dyspnea, while IAV transmission within mice does not 
occur primarily due to the preferential involvement of the deeper lungs [180, 242-245]. 
Furthermore, within mice, differences in genetic background across murine strains can influence 
the outcomes of infection. For example, it was recently shown that inconsistencies in reported 
alveolar macrophage depletion following IAV infection could be explained by mouse strain-
dependent differential responses, with decreased numbers of AM being seen in BALB/c mice, 
but not in C57BL/6 mice [246]. Moreover, the volume of inoculum in which a given infectious 
dose of IAV is given can influence infection outcome making confounding comparisons across 
studies [247]. 
Ferrets are another commonly used model and are naturally susceptible to most human 
influenza strains without the need for prior viral adaptation in addition to being supportive of 
intra-species transmission [242, 248-250]. Furthermore, ferrets are considered the best model 
for recreating human disease, and like humans, infection with seasonal IAV strains primarily 
causes upper respiratory tract infections in contrast with the lower-respiratory tract infections 
seen in mice [242, 248-250]. However, their size, expense, handling requirements, and reduced 
reagent availability, has limited their use [248]. Guinea pigs can support replication of human 
viral isolates without prior adaption and can sustain IAV transmission, but disease following 
infection in guinea pigs is clinically unapparent [242, 243, 245, 251]. Syrian hamsters have also 
been evaluated as a model of influenza, but as with guinea pigs, while they are susceptible to 
infection to infection without viral adaptation, disease is clinically unapparent [252-254]. 
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Nonhuman primates have also been used in IAV research due to their genetic and physiological 
similarities with humans, but their use is rare due to their high cost and limited availability [242, 
243, 255].  
 
Influenza A virus pathogenesis  
Infection with IAV generally results in mild to moderate infections of the upper 
respiratory tract characterized by the rapid onset of symptoms that often including fever/chills, 
sore throat, fatigue, nasal congestion, dry cough, rhinorrhea, headache, anorexia and malaise 
[256-259]. Gastrointestinal symptoms are also frequently reported including nausea, abdominal 
pain, vomiting, and diarrhea [257, 260]. In some instances (i.e., with severe infection or 
following infection with highly virulent strains), infection can spread to the lower respiratory 
tract with disease progressing to include both viral and bacterial pneumonia, edema, alveolar 
hemorrhaging, acute respiratory failure, and death [261-263]. Extra respiratory complications 
have also been reported, and include cardiac insufficiency, conjunctivitis, neurological 
involvement (e.g. Guillain-Barre syndrome and Reyes syndrome), and liver disfunction [263, 
264]. Furthermore, age and the presence of comorbidities, have been shown to alter the clinical 
presentation of IAV infection (e.g. reduced fever in the elderly) [265, 266].  
Disease following IAV infection is largely immune mediated with many of the same 
immune components needed to control the viral infection contributing to disease when 
excessive or improperly regulated [228, 267, 268]. Infection of epithelial cells and subsequent 
innate immune cell activation can result in the massive release of proinflammatory cytokines 
(i.e., interferons, IL-1β, IL-6, IL-8 and TNFα) and chemokines (i.e., CCL3 and CXCL1) [269-271]. If 
improperly regulated, this cytokine storm can lead to excessive cellular infiltration, pulmonary 
inflammation, tissue damage and loss of function [269-271]. In addition to the magnitude of the 
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cytokine and chemokine response, aberration in the timing and location of these responses can 
contribute to disease and loss of tissue function [269]. Differences in the numbers and kinetics 
of immune cell influx into the lungs during infection can also greatly impact IAV pathogenesis 
[272-274]. For example, CD8+ T cells play a critical role in controlling viral replication by direct 
killing of virally infected cells and the production of antiviral cytokines including TNFα and IFNγ 
[231, 275, 276]. Conversely, IFNγ production by CD8+ T cells is associated with impaired lung 
function [232] and CD8+ T cells have been shown to damage uninfected epithelial cells and 
reduce barrier function through TNFα and IFNγ production [277]. Protection from severe disease 
with influenza requires a balance between mounting an adequate immune response to control 
IAV infection, while subsequently promoting is contraction [267, 278], but mechanisms 
regulating these processes are only partially known.   
 
Risk factors for severe influenza 
Not all groups are at equal risk for severe or complicated disease following IAV infection, 
with several biological host factors being identified to contribute to increased disease severity. 
Notably, these include advanced age, sex, obesity, pregnancy, chronic immunosuppression, and 
the presence of comorbidities such as emphysema and cardiovascular disease [262, 279-285]. 
Females generally mount more robust immune responses to both infection and vaccination than 
males with greater cell-mediated and humoral immunity often being reported in both humans 
and in animal models [56, 143, 145, 286]. Conversely, these differences in immune response can 
also lead to enhanced immunopathology, and in the case IAV, worsen infection outcomes [145, 
148, 286-289]. In women of reproductive ages, the rates of clinical infection, hospitalization, and 
mortality have been all observed to be higher in females of reproductive ages relative to age 
matched males [144, 290-293]. In contrast, during the 1918 H1N1 influenza pandemic, infection 
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was disproportionately fatal in young adult males (i.e., 20-40 years of age) [294, 295]. In murine 
models, most, but not all, studies shown that infection with either H1N1, H3N2, or H7N9 viruses 
results in greater pulmonary immune activation and increased disease severity in female relative 
to male mice [164, 287, 296-301]. For example, pulmonary concentrations of proinflammatory 
cytokines (e.g., TNF-α, IFN-γ, IL-6, and IL-12) and chemokines (e.g. CCL2, CCL5, and CCL12) are 
greater during IAV infection in females than males [164, 287]. Moreover, following IAV infection, 
males also repair damaged pulmonary tissue faster than females at least in part through 
increased expression of the epidermal growth factor amphiregulin [302]. Though of potential 
therapeutic significance, the mechanisms underlying the differences between males and 
females are unclear, but differences in sex steroid signaling (i.e. androgens), sex chromosome 
complement, and epigenetic regulation, have been proposed [145, 288, 303].  
Disease burden and cost of influenza are disproportionally highest among individuals 
over the age 65. Despite higher infection rates in infants and children [304], individuals over the 
age of 65 account for 54 to 70% of all influenza related hospitalizations and 70 to 90% of all 
influenza related deaths in the United States [181, 305], while among individuals 65 years or 
older, males are more likely than females to be hospitalized and succumb to seasonal influenza 
[291, 306]. In China, older males have been shown to 2.4 times more likely to die following 
exposure to H7N9 than their female counterparts [307]. In Australia, a male bias has been 
reported in the relative rate of those seeking medical care for both seasonal and 2009 pandemic 
H1N1 IAV infection in elderly age groups despite a female bias in reproductive age cohorts [293]. 
Though few murine studies have used male mice, aged mice have altered pulmonary 
inflammatory responses, reduced numbers and activity of virus-specific CD4+ and CD8+ T cells 
during virus clearance, lower antibody responses to live virus and vaccines, and greater disease 
severity than their young adult counterparts [273, 308, 309]. Whether age-related changes in 
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sex hormone concentration contribute to the male bias in IAV severity has not been adequately 
explored.  
Recently obesity was recognized as an independent risk factor for severe complications 
following IAV infection after it was associated with an increased risk of hospitalization and death 
during the 2009 H1N1 IAV pandemic [310-313]. These clinical observations have since been 
recreated in murine models of obesity, where obese mice, whether diet or genetically induced, 
experience increased clinical severity, increased lung damage, and increased mortality relative 
to non-obese controls [314, 315]. In studies of both mice and humans, obesity is associated with 
higher levels of proinflammatory cytokines and chemokines (e.g., IL-1β, IL-6, CXCL2 and CCL2), 
dysregulation of CD4+ and CD8+ T cell responses (e.g., decreased IFN-γ, granzyme B, and IL-12r 
expression), and the impaired ability to resolve pulmonary damage following IAV infection [316-
318]. Furthermore, in both mice and humans, obesity is associated impaired antibody and 
memory CD8+ T cell responses to IAV vaccination [319, 320]. Notably, obesity in males has been 
associated with reduced serum testosterone concentration, but implications of this on IAV 
pathogenesis are unclear [321-323].  
Taken together, these data suggest that in males, low testosterone may be associated 
with increased severity of IAV infection. Given its well described immunoregulatory role, I 
hypothesize that testosterone reduces the severity of IAV infection by controlling inflammation 
and regulating the immune response to infection.  
 
Malaria Vaccination 
Introduction to malaria  
Malaria is caused by single-celled Plasmodium parasites belonging to the phylum 
Apicomplexa [324].  These parasites exist in complex life-cycles alternating being infection of an 
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invertebrate vector and infection vertebrate hosts including reptiles, birds, and mammals [325]. 
Over 200 species of Plasmodium have been described with each species exhibiting relatively 
high host vector and vertebrate host specificity [325, 326]. Infection in humans is primarily 
caused by four species of malaria: P. falciparum, P. malariae, P. ovale, and P. vivax [324]. 
Zoonotic spillover of a 5th species, P. knowlesi, has been observed in Southeast Asia, and can 
cause severe and sometimes fatal infections in humans [327]. Humans become infected with 
malaria following sporozoite inoculation during female Anopheline mosquito blood feeding [324, 
328]. Following inoculation, Plasmodium sporozoites travel through the bloodstream to the liver 
and establish the hepatic cycle (i.e., pre-erythrocytic stage) of malaria infection [324, 328, 329]. 
In this stage, sporozoites invade hepatocytes, maturates into schizonts, and releases thousands 
of merozoites into the bloodstream following maturation [324, 328]. Once in the blood stream, 
the merozoites go on to infect red blood cells establishing the erythrocytic stage of infection 
[324, 328]. The erythrocytic stage of malaria infection is characterized by episodic cycles (i.e., 
every 2-3 days) of red blood cell invasion, merozoite replication, and lytic release from the 
infection red blood cells [324, 328-330]. A portion of merozoites, for reasons that are not 
entirely clear, will go on to develop into gametocytes which are the sexual stage of Plasmodium 
lifecycle and the stage infectious to the Anopheline mosquito [324, 328]. Following mosquito 
infection during blood feeding, the gametocytes undergo sexual reproduction, and reestablish 
salivary gland infection as sporozoites after several rounds of replication and maturation [324, 
328]. Each stage of this life-cycle is characterized by complex biological differences in parasite 
physiology that carry unique consequences for the host, and significant variation between 
malaria strains occur [324, 328-330].  
Despite a 30% decline in clinical disease and 47% decline in mortality between 2000 and 
2013, malaria continues to represent a significant global burden of disease [331]. In 2017, 
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malaria was estimated to result in 216 million clinical cases and 445,000 deaths [332]. This was 
mostly in infants and young children, and worldwide, malaria accounts for approximately 5% of 
all under 5 child mortality [333]. Of fatal cases, more than 90% occur in sub-Saharan Africa and 
are attributable to infection with P. falciparum [328]. The disease presentation of malaria is 
complex and varies by the malaria species and age of the patient involved [334]. The hepatic 
stage is largely asymptomatic, while symptomatic disease primarily occurs as a result of lytic 
parasite release during blood stage infection [324, 328]. Uncomplicated disease in humans 
ranges from asymptomatic infection to non-specific moderate disease characterized by fever, 
chills, headache, profuse sweating, diarrhea, jaundice vomiting and anemia [324, 328, 330], with 
the onset of symptoms appearing 10 to 15 days following infection [330]. Severe malarial 
infections are often attributed to P. falciparum infection with and can result in severe anemia, 
cerebral involvement, coma, pulmonary complications, hyperglycemia, and acute kidney failure 
and death [330, 334]. Furthermore, malaria in pregnancy can involve parasitic invasion of the 
placenta leading to poor outcome for both the fetus and mother [335].  
In response to this high public health burden, the World Health Organization has set out 
a strategy to achieve a 90% reduction in malaria cases and mortality by the year 2030 [336]. 
Current methods to interrupt malaria transmission include the early diagnosis and treatment of 
cases, vector control (e.g. insecticide-treated bed net use and residual indoor insecticide 
spraying), prophylactic drug treatment, and healthcare capacity improvements [337]. However, 
these interventions are economically costly and are unlikely to achieve these goals on their own 
in the presence of increasing antimalarial drug and insecticide resistance [337-341]. To 
complement the above listed approaches to malaria control, the need for a malaria vaccine that 





Despite the high development costs to date, an effective vaccine and implementation 
strategy would likely be the most cost-effective method for controlling malaria [328, 337]. 
However, given the extraordinary complexity of the malaria parasite and it’s life-cycle, thus far 
malaria vaccine development has been largely unsuccessful [328, 337]. Due to its high 
contribution to global disease, P. falciparum has been the primary target vaccine develop, while 
vaccines targeting P. vivax  are also in development [331]. As a result of the complexities of the 
malaria life-cycle and the resulting changes in Plasmodium antigen expression varies by 
developmental stage, and vaccines can be broadly classified into categories based on the life-
cycle stage that target [331, 343, 344]. Transmission blocking vaccines target the sexually 
reproductive gametocyte stage of malaria with aim of blocking the establishment of infection in 
the mosquito [345, 346]. In this potential vaccine strategy, the result of immunity generated 
through vaccination, is not a reduction in disease in the recipient, but rather the interruption of 
transmission within a vaccinated population [345, 346]. Other vaccines in early stage 
development, include those that target the blood, or erythrocytic, stage of infection which aim 
to reduce clinical disease associated with malaria infection, by target merozoite protein 
expression [331, 343, 347, 348]. 
The most successful candidate vaccines to date, target the pre-erythrocytic stage (i.e. 
sporozoite stage) of malarial infection with the goal of blocking hepatic invasion and subsequent 
progression to blood stage infection [331, 344, 349]. However, with this strategy, sterile 100% 
protective immunity is required to prevent parasite escape and life-cycle progression [331]. 
Currently vaccines are in development based on both whole sporozoite vaccine models (e.g., 
intravenous inoculation with radiation attenuated or genetically attenuated sporozoites) as well 
peptide-based vaccines that primarily targeting the circumsporozoite protein (CSP), which is the 
30 
 
immunodominant antigen expressed by sporozoite stages. [331, 344, 349]. Including in this 
category is the RTS,S/AS01 vaccine which is the leading candidate malaria vaccine and is 
currently undergoing pilot implementation in several regions of sub-Saharan Africa [342]. The 
RTS,S/AS01 vaccine consists of the carboxy-terminal region of the P. falciparum CSP surface 
protein along with the hepatitis B surface antigen. In Phase III clinical trials, the RTS,S/AS01 
vaccine was shown to be moderately efficacious with 18-36% protection against clinical disease 
in young boys and girls (i.e., 6-12 weeks and 5-17 months) [350]. Though protection induced by 
the RTS,S/AS01 vaccine is far lower than 75% vaccine efficacy target, it represents a substantial 
improvement over previous vaccine designs [342]. 
 
Animal models for malaria research 
 As with influenza, mice are the primary animal model for malaria research and this 
preference is driven by their small size, low cost, ease of animal husbandry, and the wide 
availability of mouse-specific reagent reagents [326, 351, 352]. However, the relative high host 
specificity of Plasmodium species, prohibits their use in the study of malaria species that cause 
disease in humans and limits their use for pre-clinical research [326, 351, 352]. Instead rodent 
specific Plasmodium species are commonly used including P. berghei, P. yoelii, and P. chabaudi 
[326]. Though disease is often similar, substantial genetic and physiological differences between 
rodent and human species of malaria can make interpretation and translation of findings 
difficult [353]. Furthermore, not all aspects of infection with human species of malaria can be 
modeled in traditional rodent models [326, 354]. To circumvent some of these limitations, and 
facilitate the study of human species of malaria (i.e., P. falciparum) in a small animal models, 
both transgenic and humanized mice that contain human genes or tissues have developed [326, 
354]. For example, humanized mice containing human liver cells or transplanted tissues can be 
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used to study P. falciparum pre-erythrocytic stage infection [326, 355]. To facilitate pre-clinical 
vaccine study and evaluate antigenicity of potential target antigens, transgenic parasites have 
been also been developed that allow for study of human malaria parasites in mice [356]. As an 
example, for all studies presented in Chapter 4 of this dissertation, transgenic P. berghei 
parasites expressing a P. falciparum CSP construct were used [357].  
 Despite limitations including ethical concerns, large size, high cost, and outbred genetic 
background which limits reproducibility, nonhuman primates (NHP) play a valuable role in 
malaria research [326, 355]. The primary advantages conveyed using NHPs is their susceptibility 
to human malaria species, similar disease presentation, and physiological similarities to humans 
[326, 355]. These characteristics make them ideal pre-clinical models for vaccine trials, safety 
and efficacy evaluation of treatments and interventions, and for pathogenesis studies. In NHP 
species not supportive of infection with human malarial species, research is facilitated by the 
use of  P. cynomolgi, which is more closely related to human malarial parasites than those that 
infect rodents [326, 355]. 
 
The effects of sex and sex-hormones on malaria infection and vaccination  
 Among humans, both the incidence and intensity (i.e. parasite density) of Plasmodium 
infection is often greater in men than in women, with both adult and juvenile males being more 
likely than females to be asymptomatically infected [147, 358-365]. However, despite the male 
bias in infection frequency and intensity, malaria is often more severe in both juvenile and adult 
females, with the frequency of hospitalization, sepsis, anemia, shock, and mortality being more 
common in female patients [148, 362, 366-373]. Furthermore, women have been observed to 
be at a greater risk of death from acute respiratory distress syndrome (ARDS) following P. vivax 
infection relative to men, while pregnancy has been identified as an independent risk factor for 
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both the development of severe malaria and for mortality following the diagnosis of cerebral 
malaria [374-376]. Though gender differences in societal roles and care seeking behaviors are 
likely to contribute to some of the observed differences in the outcomes of malaria infection 
[377, 378], observations that both Plasmodium parasite density as well the frequency of malaria 
positive blood smears increases in males relative to females with the onset of puberty suggests 
that biological factors such as testosterone levels are likely to be involved [146, 360] . Consistent 
with this idea, in adult males, serum testosterone concentrations have been positively 
correlated with P. vivax parasite load, suggesting that testosterone may inhibit resistance to 
malaria infection [379]. 
As with humans, sex differences in the outcomes of infection have also been described 
in murine models of malaria. However, in contrast with observations in humans, the severity of 
infection with both P. chabaudi and P. berghei is often greater in male than in female mice, with 
males generally experiencing greater mortality and being slower to recover from infection 
induced anemia, body mass loss, and hypothermia [380-382]. Moreover, infection in female 
mice results in reduced parasitemia and a more robust immune response to infection (e.g. 
increased IFNγ, IL-10, TNFα and plasmodium-specific IgG1 and IgG2b antibody production) 
relative to males [380, 382, 383], suggesting that females may be more resistant to infection. In 
P. berghei models of cerebral malaria, increased evidence of oxidative stress in the brain (e.g., 
increased nitric oxide concentrations), and disruption of neurotransmitters (i.e., dopamine, 
epinephrine, and serotonin) is seen in males relative to females [382]. Further, more 
pronounced disruption of the urogenital tract has been described in male mice infected with P. 
chabaudi [384].  
In mice, testosterone is associated with reduced resistance to P. chabaudi and P. 
berghei blood stage infection in both males and females [381, 385-389]. Castration of male mice 
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reduces, while subsequent testosterone treatment increases, mortality and worsens blood-
stage infection severity [386, 390]. This increased survival in testosterone-depleted males is 
associated with increased total leukocyte numbers and the greater proliferative potential of B 
and T cell populations following Plasmodium infection, while NK cell populations are reduced in 
these same mice [383, 386, 389]. In female mice, testosterone treatment also increases 
mortality following P. chabaudi infection, with these effects persisting following withdrawal of 
testosterone treatment while being associated with downregulation of hepatic proinflammatory 
genes (e.g., Ifnγ and Igk-C) [390, 391]. Consistent with estrogen playing a protective role, 
gonadectomy of female mice (i.e., depletion of estrogen), reduces survival following 
Plasmodium infection relative to intact females [385, 390]. In contrast, others have reported 
that estrogen treatment of both male and female C57BL/10 mice inhibits the acquisition of 
immunity to P. chabaudi by naïve mice, but does not reduce pre-existing immunity [392].   
Sex differences in vaccine-induced immune responses are well documented for vaccines 
that protect against viruses and bacteria [57, 166], but the implications of sex differences in the 
response to potential vaccines targeting parasitic infections, including candidate vaccines 
against malaria are rarely considered. In Phase I immunogenicity trials of the malaria candidate 
vaccine SPf66, a synthetic peptide-based vaccine targeting the blood stage of P. falciparum, 
adult women (n = 4) were observed to mount greater humoral responses and PBMC 
lymphoproliferation followed peptides stimulation than men [348]. Consistent, with 
observations that female mice are more resistant to Plasmodium infection, females have been 
shown to be better protected against challenge than males following vaccination with the 
surface membranes of P. chabaudi-infected red blood cells [168]. To date, no pre-clinical study 
has been adequately designed or analyzed to study sex differences in the immunogenicity and 
efficacy of pre-erythrocytic stage malaria vaccination. Additionally, the  RTS,S/ASO1 vaccine has 
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been associated with higher all-cause mortality in girls, but not in boys, in both age groups in 
which the vaccine was tested [393]. Whether this sex-dependent vaccine outcome represents a 
difference in the immune response to RTS,S/ASO1 vaccine is unknown.  
Taken together, these data suggest that females may better protected following pre-
erythrocytic stage malaria vaccination. Given the well characterized immunosuppressive 
properties of testosterone, I hypothesize that testosterone in males will suppress both cell-



















Specific Aim 1 
 The severity of influenza increases with age, with hospitalization and death rates 
generally being higher in older males than in age-matched females. In males, circulating 
testosterone levels also decline with age, and I hypothesized that reduced testosterone 
concentrations in aged males contribute to age associated increases in influenza severity. To 
assess the role of testosterone in the severity of IAV infection, I first used a model where, young 
adult and aged male mice were left intact and infected with a low dose of IAV. As testosterone 
can reduce inflammatory responses, I hypothesized that higher testosterone concentrations in 
young males would specifically lead to reduced pulmonary inflammation. 
To reduce the influence of age-related factors other than testosterone on the severity of 
IAV, I next surgically reduced testosterone in young adult male mice and exogenously replaced 
testosterone in aged male mice. To date, no studies have assessed the effects of testosterone 
replacement on infection in aged males. I hypothesized that the depletion of testosterone in 
young males would increase, while the replacement of testosterone in age males would reduce 
the severity of IAV infection.  
 










Specific Aim 2 
 My findings from Specific Aim 1 suggested that low testosterone, whether age-related 
or surgically induced in young males, increased the severity of influenza virus infection. These 
effects were most pronounced during the recovery phase of infection (i.e., after virus had been 
cleared), and were associated with the delayed resolution of pulmonary inflammation in young 
males, independent of changes in viral replication. As few studies have directly evaluated the 
effects of testosterone on the immune response to viral infection, I wanted to further evaluate 
whether the delayed resolution of pulmonary inflammation was associated with the changes in 
the immune response to the virus. I hypothesized that testosterone was reducing the severity of 
IAV infection by accelerating the contraction of the immune response following control of viral 
replication. Given that CD8+ T cells are major contributors of both viral clearance and immune-
mediated pathology, I further hypothesized that testosterone may be acting to promote the 
resolution of CD8+ T cell responses following viral clearance. 
 In this Specific Aim 2, I elected to evaluate the effects of testosterone on the immune 
response to IAV using young adult male mice to eliminate other age-related changes that may 
be occurring. For these studies, I also used the androgen receptor antagonist flutamide and non-
aromatizable dihydrotestosterone to confirm that the effects of testosterone were mediating 
through androgen receptor signaling and not through estrogen receptor signaling. I hypothesize 
that the protective effects of testosterone on IAV pathogenesis are mediated through direct 







Specific Aim 3 
 Adult females tend to develop greater adaptive immune responses than males following 
receipt of either viral or bacterial vaccines, in both preclinical animal studies and human clinical 
trials. While there is currently no approved malaria vaccine, several anti-sporozoite vaccines, are 
in development. Few studies have considered the influence of sex and sex hormones on the 
efficacy of vaccines targeting parasitic infections including malaria. Consistent with data from 
viral and bacterial vaccines, I hypothesized that females would mount greater immune response 
and be better protected following challenge than males. To date, no studies have assessed the 
effects of testosterone on the efficacy of pre-erythrocytic stage malaria vaccination. Given that, 
testosterone was observed to be immunosuppressive in Specific Aims 1 and 2, I further 
hypothesized that testosterone would suppress adaptive immune responses and protection 
following vaccination.  
 In this Specific Aim 3, I used a well-established whole sporozoite vaccine model, where 
both adult or juvenile male and female mice were vaccinated twice with irradiated transgenic P. 
berghei sporozoites expressing the P. falciparum CSP protein. Forty-five following the second 
inoculation, mice were challenged with transgenic P. berghei via mosquito bite or intradermal 
challenge. For these studies, I also elected to study the influence of male and female sex 
hormones on sex-specific differences infection through surgical castration. I hypothesize that 
the depletion of female specific sex hormones would reduce, while the depletion of 
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Influenza severity increases with age, with hospitalization and mortality rates during 
seasonal influenza epidemics being higher in older men than age-matched women. Based on 
knowledge that with age, circulating testosterone levels decline in males, we hypothesized that 
reduced testosterone contributes to age-associated increases in influenza severity. A murine 
model was used to test this hypothesis. As in men, testosterone concentrations were lower in 
aged (18 months) than young (2 months) male C57BL/6 mice. Following inoculation with 
influenza A virus (IAV), aged males experienced greater morbidity, clinical disease, and 
pulmonary inflammation than young males, and had lower neutralizing and total anti-influenza 
IgG antibody responses. Peak titers of virus in the lungs did not differ between aged and young 
males, but virus clearance was delayed in aged males. In young males, removal of the gonads 
increased, whereas treatment of gonadectomized males with testosterone reduced, morbidity, 
clinical illness, and pulmonary pathology, but did not alter viral replication. Treatment of aged 
males with testosterone improved survival following infection but did not alter either virus 
replication or pulmonary pathology. These results indicate that low concentrations of 
testosterone, whether induced surgically in young males or naturally occurring in aged males, 











Every year in the United States, the disease burden and cost of influenza is 
disproportionately highest among individuals over age 65. Ninety percent of deaths from 
seasonal influenza are in people over 65 years of age [394]. Although it is well established that 
immune protection declines in aged individuals, sex-based differences in immunosenescence 
are not often considered [395]. It has been reported that among unvaccinated individuals 65 
years or older, males are more likely than females to be hospitalized and succumb to seasonal 
influenza [291, 306]. During the H7N9 outbreak in China, older males were 2.4 times more likely 
to die following exposure to H7N9 than their female counterparts [307]. In aged individuals who 
receive either the standard or high dose trivalent inactivated influenza vaccine, antibody titers 
are 2 to 3-times lower in males than females [395, 396]. The mechanisms that mediate reduced 
protection against influenza in aged males have not been reported.  
As in humans, murine studies suggest that dysregulated immune function in aged 
individuals underlies severe outcome from influenza A virus (IAV) infection. In response to IAVs, 
aged mice have elevated pulmonary inflammatory responses [273], reduced numbers and 
activity of virus-specific CD8+ T cells during virus clearance [308], and lower antibody responses 
to live virus and vaccines [309] than their young adult counterparts. An informal analysis of the 
literature revealed that, as in humans, most murine studies on age-associated changes in IAV 
pathogenesis and vaccination either do not report the sex of the mice (~50%) or use female 
mice only (~35%). A minority use either mixed sexes or male mice, which follows general 
published trends in the fields of immunology and infectious diseases [397].  
In men, there is a gradual decline in testosterone secretion that begins after age 30, 
with the signs and symptoms of testosterone deficiency typically presenting after age 65 [398]. 
Age-related reductions in testosterone production are associated with symptoms including 
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decreased libido, erectile dysfunction, fatigue, depression, reduced strength, bone loss, and 
increased abdominal fat [31]. Although concerns about the effects of testosterone replacement 
on cardiovascular disease have been raised [399], most studies suggest that testosterone 
replacement in aged males with hypogonadism results in health and quality of life benefits [31, 
399, 400]. To date, there are no studies that have considered the immunological consequences 
of testosterone replacement in aged males. We hypothesize herein that reduced testosterone 
concentrations are detrimental for susceptibility to and the outcome of influenza, and that 
susceptibility would be reduced, and the outcome improved by testosterone replacement. With 
the knowledge that testosterone can signal through androgen receptors in immune cells to 
regulate responses to immunological stimuli, including viruses and vaccines [104, 148], and that 
exogenous treatment of young adult male mice with testosterone generally reduces the 
synthesis of proinflammatory cytokines (e.g. IFN-γ and TNF-α), increases anti-inflammatory 
cytokines (e.g. IL-10), and reduces helper T cell type 1 (Th1) activity [23], we further hypothesize 
that elevating serum testosterone levels in both hypogonadal young and aged males would 












Materials and Methods 
Animals 
Young (10-12 weeks of age) and aged (17-18 months of age) adult male C57BL/6 mice were 
obtained from Charles River or the National Institute of Aging, respectively; and housed 3 to 5 per 
microisolator cage under standard BSL-2 housing conditions, with food and water ad libitum. All 
animal procedures were approved by the Johns Hopkins University Animal Care and Use 
Committee. Experiments were conducted as a series of replicates and animal numbers are 
provided in the legends. 
 
Gonadectomy, Testosterone Administration and Quantification 
Young adult male mice were anesthetized with ketamine/xylazine cocktail and bilaterally 
gonadectomized as previously described [164, 298]. All animals were given two weeks to 
recover from surgery prior to testosterone treatment. Testosterone was administered by 
subcutaneously implanting a silicone capsule (0.040 in inner diameter, 0.085 in outer diameter, 
7.5 mm length) containing 100% crystalline testosterone propionate (Sigma) between the 
scapulae. The capsules were equilibrated in sterile physiological saline for 12 h at 37oC prior to 
implantation. Animals in the placebo group received implants of empty capsules. Testosterone 
concentrations in serum were measured by radioimmunoassay using antibodies from Fitzgerald 
(Acton, MA) and tracer testosterone ([1,2,6,7-3H(N)]-Testosterone) from PerkinElmer (Waltham, 
MA) or EIA (Immuno-Biological Laboratories, Inc.) following a standard steroid extraction. All 
males were treated with testosterone for one week prior to infection.  
 
Virus Infection and Quantification 
The mouse-adapted H1N1 influenza A viruses (IAVs), A/Puerto Rico/8/34 (PR8: H1N1; courtesy of 
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Dr. Maryna C. Eichelberger) or A/California/4/09/H1N1 (ma2009; H1N1; generated by Dr. Andrew 
Pekosz using a published sequence [401]) were used in all experiments. Mice were anesthetized 
and then intranasally inoculated with 30µl of DMEM for the mock-infection or maH1N1 diluted in 
DMEM (PR8 = 0.05 MLD50; ma2009= 0.1 MLD50). For virus quantification, log10 dilutions of lung 
homogenates were plated onto a monolayer of Madin-Darby canine kidney (MDCK) cells in 
replicates of 6 for five days at 32oC. Cells were stained with naphthol blue black (Sigma Aldrich) 
and scored for cytopathic effects (CPE). The 50% tissue culture infectious dose (TCID50) was 
calculated according to the Reed-Muench method and was used to back titer all inoculums. 
 
Sample Collection 
Body mass and rectal temperature were recorded daily for 21 days and clinical disease scores 
were recorded at selected time points during the morbidity studies. Clinical disease scores for IAV 
infected mice were based on five points, with one point given for each of the following: dyspnea, 
piloerection, hunched posture, absent escape response, and a fifth point given if deceased [402]. 
For terminal studies, males were euthanized at designated days post-inoculation (dpi), at which 
time serum and whole lungs were collected.  
 
Lung Inflation and Histopathology 
Lungs were inflated at constant pressure and then fixed for 48 h with buffered zinc formalin 
fixative (Z-Fix, Anatech). Lungs were embedded in paraffin, cut into 5µm sections, and mounted 
on glass slides. Consecutive tissue sections were stained with hematoxylin and eosin for 
histopathological scoring. Tissue sections were evaluated for vascular, bronchiolar or alveolar 
inflammation and edema, and were assigned a score on a 0-3 scale (0 = no inflammation, 1 = mild 
inflammation, 2 = moderate inflammation, and 3 = severe inflammation). The cumulative 
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inflammation score represented the sum of each individual inflammation parameter. The 
percentage of affected lung area within each section was calculated from binary images created 
using ImageJ software (NIH), and values represent the average of three random 10X fields within 
each tissue section [403]. Scoring was performed by a single blinded observer in consultation with 
a boarded veterinary pathologist. Representative images were taken using a Nikon Eclipse E400 
at 20x magnification.  
 
Antibody Neutralization Assay  
Serum samples were added to serum-free infection media and serially diluted (1:2 dilutions). 
One hundred TCID50 units of virus were added to the diluted samples and incubated at room 
temperature for 1 h. The diluted samples and virus were added to MDCK cells at 100% 
confluence in 96 well plates and incubated overnight at 37oC. After 16-18 h of incubation, the 
inoculums were removed, the cells were washed with PBS plus calcium and magnesium, fresh 
infection media was added, and the cells were incubated for 5 days at 32oC. Each sample 
dilution series was run in quadruplicate and the titer was calculated as the highest serum 
dilution that eliminated virus CPE in 2 out of 4 wells per dilution. 
 
Anti-influenza total IgG ELISA 
ELISA plates (Microlon 96 well high binding plates; Greiner Bio-One) were coated overnight at 
4oC with 100 ng of purified PR8 or ma2009 virus, after which plates were washed and blocked 
for 1 h with blocking solution (10% dry skim milk powder in PBS). Plates were washed, duplicate 
diluted serum samples were added in a 2-fold series starting at 1:1000, and plates were 
incubated at 37oC for 1 h. Anti-mouse IgG secondary antibody (1:5000; Peroxidase AffiniPure 
goat anti-mouse IgG; Jackson Immunoresearch Laboratories) was added and plates were 
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incubated for 1 h at 37oC. Reactions were developed with 3,3’,5,5’ tetramethylbenzidine (TMB; 
BD Biosciences) and stopped using 1N HCL. Plates were read at 450 nm absorbance on a plate 
reader. To determine the antibody titer, a cutoff value was determined by multiplying the 
average ELISA values of serum from naïve animals at each dilution by 3. The sample ELISA titer 
was the highest serum dilution of that sample series with a value above the cutoff.  
 
Statistical Analyses 
Morbidity and clinical data were analyzed with a MANOVA with one within-subjects 
variable (days) and one between-subjects variable (treatment), and significant interactions were 
further analyzed using planned comparisons. Antibody responses, virus titers, and 
histopathological data were analyzed using two-way ANOVAs or t-tests, and significant 
interactions were further analyzed using the Tukey method for pairwise multiple comparisons. 















Influenza virus infection is more severe in aged compared with young males  
 Circulating testosterone concentrations were 3-fold higher in uninfected young 
compared with aged adult male C57BL/6 mice (Fig 2.1A; p<0.05), which are within the ranges 
reported for inbred laboratory strains of mice [404-407]. Testosterone concentrations were also 
measured at 3, 7, 14, and 21dpi in young and aged male mice infected with a low dose of 
ma2009 (i.e., a dose previously determined to be sublethal in young male mice) and revealed 
that in young males, testosterone levels dropped during the acute phase of infection (7 dpi), but 
then rebounded during the recovery phase of infection resulting in testosterone concentrations 
that were higher than aged males at 0,3 and 21 dpi only (Fig 2.1B; p<0.05). In contrast, 
testosterone levels remained low throughout the course if IAV infection in aged male mice. 
To test the hypothesis that persistently low testosterone levels were associated with a 
worse outcome of influenza in older than younger males, mice were inoculated with a low dose 
of ma2009 virus and body mass, rectal temperature, and clinical disease were monitored for 21 
dpi. Aged male mice experienced greater body mass loss, hypothermia, clinical illness, and 
mortality than young males (Fig 2.1C-E and data not shown; p<0.05). Titers of ma2009 were 
measured at select dpi and although peak viral titers in the lungs did not differ between young 
and aged male mice, the clearance of infectious virus was significantly delayed in aged males 
(Fig 2.1F; p<0.05). In response to infection with a low dose of another IAV, PR8, aged males also 
experienced greater morbidity and clinical illness than young males (Fig 2.2A-C; p<0.05), 
illustrating that the effect of aging on severe outcome from influenza was conserved across 
historic (PR8; isolated in 1934) and contemporary (ma2009) strains of IAV.  
Histological examination of lung tissue collected at several time-points following IAV 
infection revealed significantly more pulmonary inflammation in the lungs of aged than young 
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males throughout infection period (Fig 2.3A; p<0.05). In affected areas, similar levels of 
inflammation were seen between young and aged males at 7 dpi (Fig 2.3B); however, by 11, 14 
and to the greatest extent at 21 dpi, aged males had significantly more pulmonary inflammation 
than young males (Fig 2.3B; p<0.05). When scored by structural regions of the lung, no 
differences in the distribution of inflammation were observed at 7 dpi (Fig 2.3C), whereas 
perivascular and peribronchiolar inflammation were higher in aged than young male mice at 11 
dpi (Fig 2.3D; p<0.05). There was a shift in the location of inflammation at 14 and 21 dpi, with 
increased pulmonary inflammation observed in the terminal bronchioles and alveolar spaces of 
aged males, predominantly characterized by increased edema at 14 dpi (Fig 2.3E; p<0.05) and 
increased alveolar inflammation and edema at 21 dpi (Fig 2.3F and G; p<0.05). Given the 
differences in testosterone concentrations between young and old males, and the rebound in 
testosterone concentrations seen in young, but not aged males (Fig 2.1B) which corresponded 
with improved recovery from IAV induced pulmonary inflammation (Fig 2.3B) during the 
recovery phase of infection, we hypothesized that testosterone is associated with protection 
against IAV in young male mice.   
 
Protection against influenza in young males is mediated by testosterone 
 Previous data illustrate that castration of young male mice prior to lethal IAV infection 
reduces survival as compared with testis-intact males [298]. To determine whether testosterone 
directly mediated protection of young males from IAV, young adult male mice were either left 
intact or castrated to deplete testosterone production and implanted with either placebo or 
testosterone capsules prior to infection with a low dose of PR8. Castration reduced, and 
exogenous testosterone treatment of young adult males restored, circulating testosterone 
levels to within the physiological range of testis-intact young males (Fig 2.4A; p<0.05). Following 
48 
 
infection with either PR8 (Fig 2.4A-C) or ma2009 (Fig 2.4D-F), castration of young adult males 
increased the severity of IAV, and treatment of castrated males with testosterone at 
physiological doses reduced the severity of IAV to levels comparable with testis-intact male mice 
(Fig 2.4B-E; p<0.05). Neither peak virus titers nor clearance of infectious virus from the lungs 
were affected by testosterone replacement in young male mice (Fig 2.4F).  
The lungs of castrated males treated with testosterone showed reduced total 
inflammation and faster resolution of inflammation than the lungs of placebo-treated castrated 
males (Fig 2.5A). Young castrated males treated with testosterone had less pulmonary 
pathology at 14 dpi as compared with placebo-treated males, which presented as less 
perivascular, peribronchiolar, and alveolar inflammation in the lungs (Fig 2.5B-C; p<0.05). These 
data illustrate that testosterone is one host factor contributing to protection against influenza in 
young adult male mice.  
 
Testosterone replacement improves survival from influenza in aged males  
To determine if testosterone replacement in aged males could improve the outcome of 
IAV, aged males were implanted with either placebo or testosterone capsules and circulating 
testosterone concentrations measured three weeks after implantation. Exogenous testosterone 
treatment in aged males resulted in circulating testosterone concentrations that were within the 
physiological range seen in young adult male mice and were significantly higher in the 
testosterone-treated than in the placebo-treated aged males (Fig 2.6A, p<0.05). Following 
infection with a low dose of ma2009, aged males treated with testosterone experienced similar 
body mass loss and hypothermia as compared with males treated with placebo (Fig 2.6B and 
data not shown). Despite having similar patterns of morbidity, aged males that were treated 
with exogenous testosterone experienced less clinical disease (Fig 2.6C, p<0.05) and were 
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significantly more likely to survive infection than aged males treated with placebo (Fig 2.6D, 
p<0.05). Testosterone-treatment did not affect peak virus titers or clearance of infectious virus 
from the lungs of aged males (Fig 2.6E). Replacement of testosterone in aged males also did not 
signficantly alter pulmonary pathology during the course of infection (Fig 2.6F). Taken together, 
these data suggest that testosterone treatment in aged males is associated with reduced clinical 
illness and mortality from IAV, but not through reduced virus replication or pulmonary 
inflammation. 
 
Age rather than testosterone predicts antibody responses to IAVs in males 
Antibody production and the ability of antibodies to neutralize IAVs are relative 
correlates of protection against subsequent IAV infection and for efficacy of influenza vaccines 
[408], which are reduced in aged individuals. In the present study, aged males produced 
significantly lower neutralizing and total anti-IAV serum IgG antibodies than young males against 
both PR8 and ma2009 (Fig 2.7A-D; p< 0.05 in each case). Treatment of young adult male mice 
with testosterone had no effect on neutralizing antibody responses or total anti-IAV IgG 
responses against IAVs (Fig 2.7E-H). Testosterone-treatment also did not affect either 
neutralizing or total anti-IAV IgG antibody responses against IAVs in aged male mice at 21 dpi 
(Fig 2.7I-L). These data illustrate that despite improving the outcome of influenza in both young 
and aged males, there was no effect of testosterone on antibody production in either young or 








 Like data in female mice [273, 308, 309], aging was associated with worse IAV infection 
outcomes in male mice. Aged male mice had lower concentrations of testosterone and 
experienced greater morbidity and mortality following IAV infection compared to young male 
mice. Changes in body mass were similar between both young and aged mice during the acute 
phase of infection, with both groups losing approximately 20% body mass by 8 dpi. However, 
during the recovery phase, while body mass in young males returned to baseline by 16 dpi, body 
mass in aged males did not return to baseline within the 21-day study period. This was 
associated with delayed viral clearance, persistence of clinical disease symptoms, and impaired 
resolution of pulmonary inflammation in aged compared with young males. These data suggest 
a correlation between low testosterone and severity of influenza in aged males. This was further 
supported by observations that in young males, there was a transient decline in circulating 
testosterone concentrations during the acute phase of IAV infection when pulmonary 
inflammation was high, which was followed by a rebound in testosterone levels after (i.e., 21 
dpi) recovery from IAV. The association between severe disease and declining androgen levels 
has been previously reported for IAV [164], HIV [409], and tapeworm infections [410]. 
Presumably, inflammation, and more specifically cytokine secretion, can interfere with 
steroidogenesis, including testosterone production by the testes [411], which during an acute 
infection (e.g., IAV) is transient, but during a chronic infection (e.g., HIV) can be long-term and 
lead to infertility.  
To determine the role of testosterone in mitigating IAV-associated disease in the 
absence of other age-related physiologic change, we conducted mechanistic studies in which 
testosterone concentrations were depleted by castration and replaced with exogenous 
continuous-release capsules of testosterone that increased testosterone to within the normal 
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physiological range for young adult male mice. In young males, castration followed by treatment 
with testosterone resulted in a clinical phenotype like testis-intact young males after infection 
with IAV, with testosterone reducing morbidity, clinical disease, and pulmonary inflammation. 
However, in contrast to aged males, by 21 dpi, gonadectomized young males depleted of 
testosterone returned to near baseline body mass, demonstrated minimal evidence of clinical 
disease, and resolved pulmonary inflammation to levels comparable to testosterone treated 
males. The differences between young gonadectomized males and aged males, both of which 
had low circulating testosterone, suggest that other age-related physiologic changes in addition 
to reduced testosterone may contribute to age-related susceptibility to influenza.    
In aged males, testosterone replacement reduced mortality and clinical severity, but had 
minimal effects on morbidity and pulmonary inflammation. It is possible that increased 
mortality of placebo-treated males created a bias towards animals that survived, and this may 
have masked differences between treatment groups in recovery from pulmonary inflammation 
at later time points during infection. Alternatively, other age-related physiologic changes may 
render the aged population more refractory to testosterone’s protective effects. 
 Overall, testosterone improved the outcome of IAV infection in male mice and 
physiological doses of testosterone were associated with improved outcomes following 
infection with two different strains of IAV. Although previous studies using a lethal dose of PR8 
in young male mice showed a trend for testosterone and the nonaromatizable androgen, 
dihydrotestosterone, to reduce mortality from influenza virus infection [164], using low doses of 
both PR8 and ma2009 resulted in more pronounced effects of testosterone on the outcome of 
infection. The outcome of IAV infection in testosterone-treated young adult castrated males 
resembled the outcome of infection in testis-intact male mice, suggesting that testosterone is a 
significant protective factor against influenza. 
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The biological activity of sex steroids depends on many factors, including the availability 
of the unbound ligand, receptor expression and distribution, and nuclear translocation and 
signaling. We hypothesize that testosterone may have more profound effects in young relative 
to aged male mice due to age-related changes in androgen receptor expression, nuclear 
translocation, and signaling [412-415]. Sex steroids can only have their biological effects when 
decoupled from sex hormone binding globulin (SHBG). Studies in humans demonstrate that 
SHBG levels increase with age and result in decreased bioavailability of circulating testosterone 
[416, 417]. Whether similar regulatory processes may be limiting the efficacy of testosterone 
treatment in aged male mice warrants future study. With age, if the availability of free 
testosterone or the activity of androgen receptors and associated signaling pathways are 
altered, then increasing the concentrations of testosterone may not be enough to fully reverse 
the effects of aging on influenza pathogenesis. Further, whether aging in males is associated 
with changes in the aromatization of androgens into estrogens requires consideration because 
at least in female mice, estrogens are anti-inflammatory and improve the outcome of IAV [164, 
418]. Along these lines, whether the protective effects of testosterone treatment during IAV 
infection in males are due to signaling through the androgen or estrogen receptor will be 
investigated in future studies.  
In the present study, testosterone-treatment of young males conferred protection from 
IAV-associated disease by reducing pulmonary inflammation and tissue damage during the later 
stages of infection. The precise cellular mechanisms that mediate immune modulation following 
testosterone replacement remain to be determined. In response to other inflammatory 
diseases, such as experimental autoimmune encephalomyelitis (EAE) in mice, testosterone is 
associated with expansion of regulatory T cell and Th17 populations and the reduction of Th1 
activity [120, 122]. Generally, castrated male mice have higher numbers of CD4+ and CD8+ T 
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cells than intact males [419]. Castrated male mice also have higher numbers of macrophages 
and antigen-specific CD8+ T cells following viral infection than testis-intact males [121]. 
Although testosterone-induced changes in immune function are beneficial to the outcome of 
EAE and IAV infection, these same immunological changes can be detrimental to other diseases, 
including  sepsis, trauma-hemorrhage, and wound repair, in which treatment with androgens is 
associated with depression of cell-mediated immune responses necessary for recovery [420-
422]. Characterization of the relative contributions various immune cell populations play in 
mediating the protective effects of testosterone against IAV warrants additional study.  
Human studies reveal that higher levels of testosterone are correlated with lower 
antibody responses to the trivalent inactivated seasonal influenza vaccine (TIV) [104]. In the 
current studies, manipulation of testosterone did not affect either neutralizing or total anti-IAV 
IgG titers in either young or aged male mice. Whether this reflects differences in androgen 
signaling in humans and mice, systemic immunization versus local pulmonary infection, or use of 
inactive versus live IAVs requires additional consideration. Instead, age was more likely to 
predict the antibody response to IAV, with young males having significantly higher antibody 
titers than aged males.  
Study of the hormonal effects on immune responses to IAV has focused exclusively on 
effects in young adults, and predominantly on hormonal effects in young adult females, which 
demonstrate profound effects on viral pathogenesis and immune responses to vaccination [164, 
402, 423, 424]. No studies have evaluated the relative contribution of age-related reductions in 
sex steroid levels in explaining why influenza pathogenesis and vaccine efficacy are worse in 
aged males. Whether testosterone also affects susceptibility to pneumonia following secondary 
bacterial infection, which is often a principle cause of death from influenza [425-427] warrants 
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further consideration. We now provide systematic evidence of a role for testosterone in 
mediating IAV pathogenesis in both young and aged males.  
Prescription of testosterone replacement therapy has increased as the population of 
adults age 65 and older continues to grow [398]. To date, clinical studies have focused 
exclusively on the impact of testosterone on sexual function, mental health, bone health, 
muscle mass, and metabolic and cardiovascular diseases [398, 428, 429]. These data highlight 
additional impacts of testosterone on the immune response and suggests that testosterone 
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Figure 2.1: Effects of age on the outcome of ma2009 virus infection. Circulating concentrations 
of testosterone were measured in aged (17-18 months; n=9) and young (10-12 weeks; n=7) male 
mice prior to infection (A) as well as over the course of infection (B). Following intranasal 
inoculation with a low dose of mouse-adapted influenza A virus (ma2009), body mass (C), 
clinical disease (D), and survival (E) were monitored for 21 days in aged and young adult male 
mice (n=15-34/age). Pulmonary viral titers were measured at 3, 7, 11, 14- or 21-days post-
inoculation (dpi) (F; n=4-8/treatment/time-point). Significant differences between aged and 
young adult male mice are represented by asterisks (p < 0.05). 
 
Figure 2.2: Effects of age on the outcome of PR8 virus infection. Following intranasal 
inoculation with a low dose of a historic mouse-adapted influenza A virus (PR8), changes in body 
mass (A), rectal temperature (B), and clinical disease (C) were monitored for 21 days in aged and 
young adult male mice (n=10/group). Significant differences between aged and young adult 
male mice are represented by asterisks (p < 0.05). 
 
Figure 2.3: Effects of age on pulmonary inflammation following infection with ma2009. Lungs 
were collected from young and aged males that were mock infected or infected with a low dose 
of influenza A virus (ma2009) and euthanized at 7, 11, 14, or 21 days post inoculation (dpi) (n=4-
7/age/time-point). Lung tissues were sectioned, stained with H&E, and scored for markers of 
inflammation, including perivascular inflammation, peribronchiolar inflammation, alveolar 
inflammation, and edema Cumulative inflammation scores (A), and percent affected area (B) are 
presented. Histology scores for individual inflammatory parameters were compared between 
young and aged males at each time post-inoculation (C-F). Representative photomicrographs (G) 
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are shown for lungs collected from young and aged IAV- and mock-infected males at 21 dpi. 
Significant differences between aged and young adult male mice are represented by asterisk (p 
< 0.05).  
 
Figure 2.4: Effects of exogenous testosterone-treatment on the outcome of IAV infection in 
young adult male mice. Young adult male mice were left intact or gonadectomized and either 
treated with placebo (Gdx) or time-release testosterone (Gdx + T) pellets for one week prior to 
inoculation with influenza A virus (IAV; PR8). Concentrations of testosterone (A) were measured 
in serum samples collected 21 days post-inoculation (dpi) (n = 6-17/treatment). Following 
intranasal inoculation with PR8, changes in body mass (B) and clinical disease (C) were 
monitored for 21 dpi (n = 8-10/group). A separate cohort of young adult male mice was 
gonadectomized and either treated with placebo (Gdx) or time-release testosterone (Gdx + T) 
pellets for one week prior to inoculation with a contemporary strain of IAV (ma2009). Following 
intranasal inoculation with ma2009, males (n= 13-15/treatment) were monitored for changes in 
body mass (D), clinical disease (E), and pulmonary virus titers (F). Significant differences 
between testosterone-treated and placebo-treated gdx male mice are represented by asterisks 
and significant differences between intact and placebo-treated gdx males are represented by a 
dagger (p < 0.05). 
 
Figure 2.5: Effects of testosterone-treatment on pulmonary inflammation following ma2009 
virus infection in young adult males. Lungs were collected from young adult males that were 
gonadectomized and treated with either placebo (Gdx) or testosterone (Gdx + T) and either 
mock infected or infected with influenza A virus (ma2009) and euthanized at 5, 9, 14, or 21 days 
post-inoculation (dpi) (n=6-10/treatment/time-point). Lung tissues were sectioned, stained with 
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H&E, and scored for makers of inflammation, including perivascular inflammation, 
peribronchiolar inflammation alveolar inflammation, and edema. Cumulative inflammation 
scores at 5, 9, 14, or 21 dpi are presented (A). Histology scores (B) and representative 
photomicrographs (C) are shown for 14 dpi. Significant differences between gonadectomized 
young adult male mice treated with placebo or testosterone are represented by asterisk (p < 
0.05).  
 
Figure 2.6: Effects of testosterone-replacement on the outcome of ma2009 virus infection in 
aged male mice. Aged male mice were either treated with placebo (P) or time-release 
testosterone capsules (T) for one week prior to inoculation with influenza A virus (IAV; ma2009). 
Concentrations of testosterone (A) were measured in serum samples collected 21 days post-
inoculation (dpi) (n=9-10/treatment). Following intranasal inoculation with IAV, body mass (B), 
clinical disease (C), and survival (D) were monitored for 21 dpi (n=24-34). Titers of infectious 
virus were measured 3, 7, 14, or 21 dpi (E; n=4-8/treatment/time-point). Lung tissue was 
collected from mock-infected and IAV-infected aged mice that were treated with placebo or 
testosterone and euthanized 7, 14, or 21 days post-inoculation (dpi) (n=5-10/treatment/time-
point). Lung tissue sections were scored for makers of inflammation and cumulative 
inflammation scores are presented (F). Significant differences between testosterone-treated 
and placebo-treated aged male mice are represented by asterisks (p < 0.05).  
 
Figure 2.7: Effects of age and testosterone on neutralizing and total IgG antibody responses in 
young and aged males infected with either PR8 or ma2009 virus. Neutralizing and total anti-
influenza IgG antibody titers were measured in serum samples collected 21 days post-
inoculation (dpi) with either PR8 or ma2009 in young and aged adult males (n = 4-12/virus/age; 
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A-D), gonadectomized young adult males treated with either placebo (Gdx) or testosterone (Gdx 
+ T; n = 7-12/virus/treatment; E-H), or in aged male treated with either placebo (P) or 
testosterone (T; n = 4-10/virus/treatment; I-L). Significant differences are represented by 
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Circulating androgens in males can modulate immune cell activity, but the impact of androgens 
on viral pathogenesis remains unclear. Previous data demonstrate that testosterone reduces the 
severity of influenza A virus (IAV) infection in male mice by mitigating pulmonary inflammation 
rather than by affecting viral replication. To examine the immune responses mediated by 
testosterone to mitigate IAV-induced inflammation, adult male mice remained gonadally intact 
or were gonadectomized and treated with either placebo or androgen-filled (i.e., testosterone 
or dihydrotestosterone) capsules prior to sublethal IAV infection. Similar to intact males, 
treatment of gonadectomized males with androgens improved the outcome of IAV infection, 
which was not mediated by changes in the control of virus replication or pulmonary cytokine 
activity. Instead, androgens accelerated pulmonary leukocyte contraction during the recovery 
phase of infection (i.e., after virus clearance) to limit inflammation. To identify which immune 
cells were contracting in response to androgens, the composition of pulmonary cellular 
infiltrates was analyzed and revealed that androgens specifically accelerated the contraction of 
total CD8+ T cells, IAV-specific CD8+ T numbers, and cytokine production and degranulation by 
IAV-specific CD8+ T cells, while also inhibiting the influx of eosinophils into the lungs following 
clearance of IAV. CD8+ T cells expressed androgen receptor (Ar) mRNA and the effects of 
testosterone on the contraction of CD8+ T numbers and activity were blocked by co-
administration of the androgen receptor antagonist, flutamide. Despite the presence of Ar 
mRNA in CD8+ T cells, adoptive transfer of CD8+ T cells revealed that the presence of 
testosterone in recipient rather than donor mice protected males against IAV by limiting 
inflammation associated with prolonged CD8+ T cell activity in the lungs. These data suggest 
that testosterone creates an environment that promotes downregulation of detrimental 




Testosterone, a sex steroid hormone produced and released primarily by Leydig cells in 
the testes of males, has significant effects on health and disease [430]. In men, low 
testosterone, whether congenital, acquired, or age-related, is associated with an increased risk 
of all-cause and cardiovascular related mortality [35, 40, 41]. Additionally, low testosterone in 
males has been linked to metabolic dysfunction, osteoporosis, muscle weakness, fatigue, 
cognitive impairment, and sexual dysfunction; while in hypogonadal men, testosterone 
replacement therapy has been shown to improve cardiovascular disease outcomes, increase 
quality of life perceptions, and improve age-associated anemia [41, 44-48]. Although safety 
concerns exist (e.g., cardiovascular disease risk), the perceived benefits of testosterone 
replacement therapies have resulted in a dramatic increase in its therapeutic use over the last 
two decades, with an estimated 2.3 million men undergoing testosterone replacement therapy 
in the United States alone in 2013 [49, 50]. Included in these numbers is a 4-fold increase in 
testosterone replacement therapy use in reproductively aged males (i.e. 18 to 45 years of age), 
a demographic often overlooked in studies of the implications of low testosterone [53]. Despite 
the increasing popularity of testosterone replacement therapy, the influence of testosterone 
deficiency and treatment on clinical outcomes of infectious disease has not been adequately 
considered.  
The biological effects of testosterone are typically mediated through androgen receptor 
(AR) signaling [5, 35]. Intracellular androgen receptors are present in cells throughout the body, 
with testosterone modulating the activities of a variety of tissue and cell types [35]. Notably, ARs 
are widely expressed in cells of both the innate and adaptive immune system, including 
macrophages, neutrophils, and T cells [5, 35]. In humans and nonhuman animals, testosterone 
and its physiologically active metabolite, dihydrotestosterone (DHT), are broadly 
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immunoregulatory and capable of altering the number, function, and differentiation of most 
immune cell populations. For example, in the presence of testosterone, murine macrophages 
increase IL-10 and decrease TNFα synthesis, while T cell numbers and activity (e.g., IL-4 and Il-12 
production) are reduced [70, 121]. In adult human males, clinical depletion of testosterone 
decreases regulatory T cell numbers (Tregs), reduces mitogen-induced IFNγ expression in CD8+ T 
cells, and suppresses the ability of natural killer cells to proliferate [91]. Although, the 
immunomodulatory properties of testosterone are well known, the impact of low testosterone 
on the severity of viral infection remains incompletely characterized. If testosterone is capable 
of broadly regulating the immune system, then in viral infections where pathogenesis is driven 
by the immune response rather than viral replication, testosterone is likely to protect and 
reduce the severity of infection.  
Disease following IAV infection is largely immune-mediated, with severe disease often 
associated with excessive or aberrant immune responses (i.e., a cytokine storm) to the virus 
[228, 267]. We have previously shown that low testosterone in males, whether age-related or 
surgically-induced, increases the severity of IAV infection [164, 431]. Furthermore, these 
changes were associated with delayed resolution of pulmonary inflammation, independent of 
either changes in viral replication or induction of growth factors (e.g., amphiregulin), suggesting 
that the protective effects of testosterone are mediated through changes in the inflammatory 
response to infection [302, 432]. In the current study, we sought to characterize the effects of 
testosterone on the immune response to IAV using a murine model of IAV infection. We show 
that testosterone improves the outcomes of IAV infection not by mitigating the cytokine storm, 
but by promoting the contraction of virus-specific pulmonary CD8+ T cells following control of 
viral replication. The effects of testosterone were dependent on androgen receptor signaling. 
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Despite CD8+ T cells expressing the androgen receptor, the protective effects of testosterone on 

























Materials and Methods  
Animals 
All animal procedures were approved by the Johns Hopkins Animal Care and Use Committee 
(MO18H262). Adult (7-8 weeks old) male C57BL/6 mice were purchased from Charles River. For 
adoptive transfer experiments, male and female TCR-Ova (C57BL/6-Tg(TcraTcrb) 1100MjbJ/J) 
and CD90.1 (B6.PL-Thy1 a/CyJ) mice were purchased from The Jackson Laboratory as breeding 
pairs and bred in house to obtain male offspring. All mice were housed at 3-5 animals per 
microisolator cage under standard BSL-2 housing conditions and given food and water ad 
libitum. 
 
Gonadectomy and hormone manipulation  
Adult (8 week old) male mice were anesthetized by intra-peritoneal inoculation with a ketamine 
(80 mg/kg) and xylazine (8 mg/kg) cocktail and the testes were removed bilaterally as described 
previously [164]. Following two weeks recovery, silastic tubing capsules (inner diameter-0.04", 
outer diameter- 0.085"; HelixMark) containing crystalline testosterone propionate (7.5 mm; 
Sigma), crystalline 4,5α-Dihydrotestosterone (5.0 mm; Sigma), or nothing were implanted 
subcutaneously [433]. For flutamide studies, capsules were prepared as above (2 x 15.0 mm; 
Sigma) but were implanted at the time of gonadectomy. All capsules were sealed with 2.5 mm 
of medical adhesive (Factor II, A-100) and incubated at 37°C overnight in sterile saline solution 
prior to implantation.  
 
Virus infection and quantification 
Mouse-adapted A/California/O4/09 (ma2009; H1N1; generated by Dr. Andrew Pekosz using a 
published sequence) [401] or recombinant A/WSN/33 virus containing OVA257-264 (SIINFEKL) 
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peptide in the neuraminidase protein (H1N1; WSN-Ova1) [434], were used in all experiments. 
Mice were anesthetized and infected by intranasal inoculation with ma2009 or WSN-Ova1 H1N1 
virus (ma2009 = 0.1 MLD50; WSN-OVA1 = 0.4 MLD50) diluted in 30μl of DMEM or mock infected 
with 30μl DMEM. For virus quantification, log10 dilutions of lung homogenate were plated onto 
Madin-Darby canine kidney (MDCK) cell monolayers in replicates of 6 for 5 days at 32°C. Cells 
were stained with naphthol blue black (Sigma Aldrich) and scored for cytopathic effect. The 50% 
tissue culture infectious dose (TCID50) was calculated using the Reed-Muench method and was 
used to back titer all viral inoculums.  
 
Sample collection and testosterone quantification 
Following infection, rectal temperature and body mass were recorded daily out to 21 days post 
inoculation (dpi), and clinical disease scores were recorded at select time-points as described 
previously [432]. For terminal studies, mice were euthanized at select time-points and plasma, 
whole lungs, spleen, and mediastinal lymph nodes (MLN) were collected. Seminal vesicles were 
also collected, and mass was recorded as a bio-marker for androgen activity. Total testosterone 
concentration was quantified in plasma collected at 21 dpi by commercial ELISA kit according to 
the manufacturer’s instructions (IBL America). To prevent sample degradation, care was taken 
to limit light and thermal exposure of plasma samples prior to testosterone quantification.   
 
Pulmonary cytokine and chemokine quantification 
Snap-frozen lung tissue was homogenized in DMEM supplemented with 1% L-glutamine (Gibco), 
and 1% penicillin-streptomycin (Gibco) and centrifuged to remove cellular debris. Supernatants 
were collected and Eotaxin, G-CSF, GM-CSF, IFNγ, IL-1α, IL-1β, IL-2, IL-3, IL-4, IL-5, IL-6, IL-9, IL-
10, IL-12p40, IL-12p70, IL-13, IL-17A, CXCL-1, MCP-1, MIP-1α, MIP-1β, RANTES, and TNFα were 
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quantified using the Bio-Plex Pro Mouse Cytokine 23-Plex Assay (Biorad) according to the 
manufacturer’s instructions. Pulmonary TGFβ concentration was quantified by commercial ELISA 
kit (R&D Systems). For analyses, IL-9 and IL-17A concentrations remained below the limit of 
detection at all time-points and were excluded. 
Flow cytometry 
Lung, spleen, and MLN tissues were harvested, and single cells suspensions were generated by 
homogenizing tissue through a 100μm nylon filter (Falcon) followed by ACK lysis of red blood 
cells (Quality biologicals). The total numbers of live cells were determined using a 
hemocytometer and trypan blue (Invitrogen) exclusion, and cells were resuspended at 1 × 
106 cells/ml in RPMI 1640 (Cellgro) supplemented with 10% fetal bovine serum (Fisher 
Scientific), 1% L-glutamine (Gibco), and 1% penicillin-streptomycin (Gibco). For the enumeration 
of H1N1-specific CD4+ and CD8+ T cells, isolated cells were cultured for 5hrs at 37°C in media 
containing IAV specific peptide (2009ma; CD8: NP366-374, or CD4: NP311-325, and WSN-OVA1; CD8: 
OVA257-264) in the presence of GolgiPlug (BD) and GolgiStop (BD). Following incubation, T cell 
viability was determined by fixable live/dead far red viability stain (Invitrogen). For all leukocyte 
populations, Fc receptors were blocked using anti-CD16/32 (BD Biosciences) and panel specific 
surface markers were stained with the following antibodies: CD4-PerCPCy5.5 (Clone RM1-5; BD), 
CD8-PerCPCy5.5 (Clone 53-6.7; BD), CD11b-FITC (Clone M1/70; BD), CD11C-APC (Clone HL3; BD), 
CD25-FITC (Clone 7D4; BD) CD45-PerCPCy5.5 (Clone 30-F11; BD), CD90.1-FITC (Clone OX-7; BD), 
CD90.2-PE (Clone 53-2.1; BD), CD107a-PE (Clone 1D4B; BD), Ly-6G-FITC (Clone 1A8; BD), I-A/I-E 
(Clone M5/114.15.2), Siglec-F (Clone E50-2440), PE-conjugated tetramer for ma2009 
(ASNENVETM; NIH Tetramer Core Facility), and PE-conjugated pentamer for WSN-OVA1 
(SIINFEKL; Proimmune). Cells were then permeabilized and fixed (BD Cytofix/Cytoperm) prior to 
intracellular staining with IFNy-FITC (Clone XMG1.2; BD), IL4-PE (BD), IL17A-PE (BD), and TNFα-
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PE (Clone MP6-XT22; BD). Intracellular staining with Foxp3 (Clone MF23; BD) was performed 
following fixation and nuclear permeabilization with the FoxP3/Transcription Factor Staining 
Buffer Set (eBioscience). Data were acquired using a FACSCailubr flow cytometer (BD) running 
Cell Quest Pro and analyzed using FlowJo (v.10) software (Tree Star, Inc.). Total cell counts were 
determined based on the total live cells counts acquired by trypan blue exclusion staining 
multiplied by the total live cell percentages for each corresponding gate.  
 
Real time reverse transcription PCR 
Pulmonary single cells suspensions were generated by homogenizing lung tissue through a 
100μm nylon filter (Falcon) and CD8+ T cells were isolated by negative selection (StemCell 
Technologies). Total RNA was then isolated from purified CD8+ T cells using a commercial kit 
(Invitrogen) per the manufacturer’s instructions and RNA concentration and purity were 
measured using a NanoDrop (ThermoFisher Scientific). Pre-designed androgen receptor (Ar) 
(Mm.PT.58.12425400) and Gapdh (Mm.PT.39a.1) PrimeTime Primers were purchased from 
Integrated DNA Technologies. Semi-quantitative RT-PCR was performed in 96-well optical 
reaction plates using SsoFast EvaGreen Supermix (Biorad) on the StepOnePlus RT-PCR system 
(Applied Biosystems). Gene expression was normalized to Gapdh and mock-infected samples 
using the ∆∆Ct method.   
 
Adoptive Transfer of CD8+ T cells  
Splenic tissue was harvested from unprimed gonadectomized male TCR-Ova mice treated with 
either empty capsules (gdx) or testosterone capsules (gdx + T).  CD8+ T cells were isolated by 
tissue homogenization through a 100μm nylon filter (Falcon), followed by negative selection 
purification (StemCell Technologies). One-hundred thousand purified CD8+ T cells were then 
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transferred into gdx and gdx + T treated naive male CD90.1 recipient mice via intravenous 
inoculation. Recipient mice were infected with WSN-Ova1 virus 48 hours post transfer.  
 
Statistical Analysis 
Discrete measures were analyzed by one or two-way ANOVA with significant interactions further 
analyzed using the Tukey method for pairwise multiple comparisons. Repeated measures were 
analyzed by mixed-effect model with Bonferroni’s post-test for multiple comparisons. Statistical 
analyses were performed using GraphPad Prism 8.00 software and mean differences were 



















Testosterone reduces the severity of IAV infection in male mice 
To assess the effects of testosterone on the severity of influenza virus infection, adult male mice 
underwent sham surgeries or were gonadectomized and received either testosterone or 
placebo capsules. Gonadectomized males had significantly lower concentrations of circulating 
testosterone and seminal vesicle mass than either gonad-intact or gonadectomized males that 
received testosterone (Fig 3.1A and 3.1B; p < 0.05). Following intranasal inoculation with a sub-
lethal dose of ma2009 H1N1, mice were monitored for 21 days post inoculation (dpi) for 
changes in body mass, body temperature, and clinical disease severity. Similar to previous 
studies [164, 432], testosterone-depleted mice experienced greater body mass loss, 
hypothermia, and clinical disease severity than either gonad-intact or gonadectomized males 
that received testosterone (Fig 3.1C-1E; p < 0.05). Despite these differences in the severity of 
IAV infection between testosterone-depleted and testosterone-replete mice, neither peak virus 
titers at 7 dpi nor the clearance of infectious virus from the lungs by 14 dpi was affected by 
testosterone concentrations in males (Fig 3.1F). These data illustrate that testosterone reduces 
the severity of IAV infection, independent of changes in viral replication.  
 
Pulmonary cytokine and chemokine concentrations are not altered by testosterone in males 
The severity of IAV infection is associated with profound induction of pulmonary cytokine and 
chemokine responses, which can lead to excessive cellular infiltration, pulmonary inflammation, 
and tissue damage, if improperly regulated [269, 270]. To test whether testosterone altered the 
kinetics or magnitude of the cytokine and chemokine response during IAV infection, pulmonary 
concentrations of 24 cytokines and chemokines were measured at selected time-points. 
Pulmonary concentrations of pro-inflammatory cytokines and chemokines (e.g. IL-6, G-CSF, and 
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CCL2) broadly increased in response to infection at 3 and 9 dpi, and then declined following 
control of viral replication at 14 dpi (Fig 3.2A-2E and SI Table 3.1). The only chemokine that was 
significantly altered by testosterone treatment was CXCL1, which was greater in the lungs of 
testosterone-treated, than testosterone-depleted male mice at 3 and 14, but not 9 dpi (SI Table 
3.1; p < 0.05). Despite the known anti-inflammatory effects of testosterone [125, 435, 436], 
testosterone treatment did not alter pulmonary concentrations of either IL-10 or TGFβ during 
IAV infection (Fig 3.2F and SI Table 3.1). Taken together, these data suggest that the improved 
outcome of IAV associated with testosterone is independent of substantial changes in the 
‘cytokine storm’ during IAV infection. 
 
Testosterone alters the influx and contraction of pulmonary immune cells during the 
resolution of IAV infection 
Differences in the numbers and kinetics of immune cells that influx into the lungs during 
infection can greatly impact IAV pathogenesis [272-274]. To test the hypothesis that 
testosterone affected immune cell recruitment into the lungs during IAV infection, total 
numbers of innate and adaptive immune cells were enumerated in the lungs of testosterone or 
placebo-treated gonadectomized male mice. The total number of leukocytes (i.e., CD45+ cells) in 
the lungs peaked at 7 dpi (i.e., during peak virus replication) and was followed by a greater 
decline in cell numbers in the lungs of testosterone-treated relative to placebo-treated males at 
14 and 21 dpi (i.e., after control of virus replication) (Fig 3.3A; p < 0.05).  
To identify which immune cell types persisted in the lungs of testosterone depleted males, 
we further characterized the composition of pulmonary cellular infiltrates. During IAV infection, 
the numbers of interstitial macrophages, neutrophils, plasmacytoid dendritic cells, and 
conventional dendritic cells increased in both testosterone- and placebo-treated 
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gonadectomized males, with peak numbers of innate immune cells in the lungs occurring at 7 
dpi (Table 3.1). In contrast, the number of alveolar macrophages declined over the course of 
infection in all male mice (Table 3.1).  
The only cell types affected by testosterone treatment in males were neutrophils and 
eosinophils. The number of pulmonary neutrophils was transiently greater at baseline (0 dpi) 
and 3pi, but not at other dpi, in gonadectomized males that were treated with testosterone as 
compared with those treated with placebo (Table 3.1; p < 0.05). In contrast, a significant influx 
of eosinophils into lungs occurred in gonadectomized males treated with placebo, but not 
testosterone, after clearance of virus from the lungs (i.e., 14 and 21 dpi) (Fig 3.3B; p < 0.05). The 
influx of eosinophils into the lungs of testosterone depleted males during the resolution phase 
of infection may be indicative of eosinophilic pneumonia [437], which may contribute to the 
pulmonary histological inflammation reported previously in testosterone depleted male mice 
[432]. 
In addition to affecting innate immune cells, testosterone is associated with shifts in the 
numbers, activities, and differentiation of CD4+ T cells in experimental models of allergy and 
autoimmune disease [117, 122, 125, 438]. To test the hypothesis that testosterone improved 
the outcome of IAV infection by shifting populations of CD4+ T cells, helper T cell type 1 (Th1), 
type 2 (Th2), type 17 (Th17), and regulatory T (Treg) cells where quantified at several time 
points before and during IAV infection. Peak numbers of total CD4+ T cells, Th1, Th2, Th17, and 
Treg cells occurred in both testosterone-depleted and -replete males at 9 dpi, followed by a 
retraction of cell numbers at 14 dpi (Table 3.2). The contraction of total CD4+ T cell numbers in 
the lungs was significantly slower of testosterone-depleted as compared with replete males at 
14 and 21 dpi (Table 3.2; p < 0.05). There was no effect of testosterone treatment on the 
numbers of IAV-specific Th1, Th2, or Th17 cells at any time point examined (Table 3.2). In 
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contrast with previous reports of testosterone-induced expansion of Treg cell numbers [122], 
Treg cell numbers were greater in the lungs of placebo-treated relative to testosterone-treated 
gonadectomized males, but only at 21 dpi (Table 3.2; p < 0.05). These data suggest that CD4+ T 
cells are not the primary cell type mediating the protective effects of testosterone during IAV 
infection of male mice. 
Virus-specific CD8+ T cells are beneficial for the killing of IAV-infected cells but can also be 
detrimental to the host by causing immunopathology [275, 277]. Total CD8+ as well as IAV-
specific CD8+ T cells influxed into the lungs at 9 dpi (Fig 3.3C and 3D), which corresponded with 
peak virus titers (Fig 3.1F). Testosterone had no effect on either the induction or peak 
magnitude of total or virus-specific CD8+ T cells in the lungs; the contraction of these cells, 
however, following virus clearance (14 and 21 dpi) was significantly better in testosterone-
treated as compared with placebo-treated gonadectomized males (Fig 3.3C and 3.3D; p < 0.05 in 
each case). To determine if testosterone suppressed the activity of virus-specific CD8+ T cells, we 
assessed cytokine protection following ex vivo stimulation with ma2009 H1N1-specific peptide 
and observed that the number of CD8+ T cells producing IFNγ was significantly reduced in 
testosterone treated males relative to testosterone depleted males after virus had been cleared 
(i.e., 14 and 21 dpi) but not during peak virus titers (i.e., 9 dpi; Fig 3.3E; p < 0.05). To further 
assess whether testosterone affected the functionality of IAV-specific CD8+ T cell we used 
CD107a as a marker for degranulation in response to ex vivo ma2009 H1N1-specific peptide 
stimulation. After virus had been cleared from the lungs, the contraction in the numbers of CD8+ 
T cells staining positive for both surface expression of CD107a and production of IFNγ was 
delayed in the lungs of testosterone-depleted relative to testosterone-replete male mice (Fig 
3.3F; p < 0.05). The effects of testosterone on the contraction of IAV-specific CD8+ T cells after 
virus had been cleared from the lungs, was specific to the site of virus replication and not 
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observed in either the spleen or the mediastinal lymph nodes (i.e. pulmonary draining lymph 
nodes; Table 3.3). Taken together, these data suggest that testosterone may improve the 
outcome of IAV infection by dampening immunopathology caused by pulmonary virus-specific 
CD8+ T cell populations.  
 
The protective effects of testosterone during IAV infection are dependent on androgen 
receptor signaling 
Testosterone can be metabolized in tissues, converted into estradiol, and signal through 
estrogen receptors [439]. Estradiol signaling through estrogen receptor α can dampen 
inflammation and improve the outcome of IAV infection, at least in female mice [164, 418, 440]. 
To determine whether the protective effects of testosterone during IAV infection in male mice 
were caused by signaling through androgen or estrogen receptors, male mice were 
gonadectomized and implanted with capsules containing either testosterone, placebo, or a 
combination of testosterone and the androgen receptor antagonist flutamide [441]. Seminal 
vesicle mass was used as a biomarker to confirm androgen receptor inhibition by flutamide and 
was significantly reduced in males that received testosterone + flutamide treatment as 
compared with males that received testosterone alone (Fig 3.4A; p < 0.05). During IAV infection, 
flutamide treatment inhibited the protective effects of testosterone on morbidity (Fig 3.4B and 
3.4C; p < 0.05). To assess whether the testosterone-induced changes in CD8+ T cell numbers and 
activity were also androgen receptor-dependent, we evaluated the effects of flutamide on the 
contraction of CD8+ T cells during the resolution phase of infection. Co-treatment of flutamide 
and testosterone, similar to placebo treatment, resulted in significantly greater numbers of total 
CD8+ T cells, ma2009 H1N1-specific CD8+ T cell, and virus-specific CD8+ T cells producing IFNγ in 
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response to H1N1 specific peptide stimulation at 14 and 21 dpi as compared with testosterone 
treatment alone (Fig 3.4D-4F; p < 0.05).  
Because flutamide can alter T cell function through off-target GABA-A receptor signaling 
[442], we sought to confirm the effects of androgen receptor signaling on IAV pathogenesis by 
using the non-aromatizable androgen, dihydrotestosterone (DHT) (i.e., an androgen that cannot 
be converted into estradiol). Treatment of gonadectomized males with DHT significantly 
increased seminal vesicle mass relative to placebo-treated males, to a mass consistent with 
testosterone-treated males (Fig 3.5A; p < 0.05). Males that were gonadectomized and treated 
with DHT prior to IAV infection were protected against IAV and experienced a similar level of 
morbidity (i.e., body mass and temperature loss) as testosterone-treated males, which was 
collectively better than placebo-treated mice (Fig 3.5B and 3.5C; p < 0.05). Consistent with 
testosterone, DHT accelerated the contraction of total numbers of CD8+ T cells, ma 2009 H1N1-
specific CD8+ T cell numbers, and the number of CD8+ T cells producing IFNγ in response to ex 
vivo H1N1-specific peptide stimulation relative to testosterone depleted male mice at 14 and 21 
dpi (Fig 3.5D and 3.5E; p < 0.05). These data demonstrate that the protective effects of 
testosterone on IAV pathogenesis are dependent on androgen receptor signaling in the lungs. 
 
Testosterone creates a local environment to promote the contraction of CD8+ T cells following 
control of IAV replication 
Testosterone can act both directly and indirectly to alter the biological activities of T cells 
[113, 125, 443]. For testosterone to have direct effects on the contraction of CD8+ T cells during 
IAV infection, androgen receptor expression would need to occur within these cells. Consistent 
with previous reports [97, 125, 128, 129], Androgen receptor (Ar) mRNA was expressed in 
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enriched splenic CD8+ T cells from both testosterone-depleted and testosterone-replete male 
mice, with no effect of testosterone treatment on Ar mRNA expression (Fig 3.6A). 
Because Ar was expressed by splenic CD8+ T cells, we hypothesized that testosterone could 
directly signal in these cells to induce contraction following control of viral replication. To test 
this hypothesis, TCR-Ova donor mice and CD90.1 recipient mice were gonadectomized and 
implanted with capsules containing either testosterone or placebo. Enriched splenic CD8+ T cells 
from naïve TCR-Ova mice were then adoptively transferred into either placebo- or testosterone-
treated CD90.1 recipient mice prior to infection with WSN-Ova1 H1N1 IAV. Seminal vesicle mass 
was greater in testosterone-treated recipient mice relative to placebo-treated recipient mice for 
all treatment groups (Fig 3.6B; p < 0.05). Recipient males that were gonadectomized and treated 
with testosterone prior to IAV infection were protected against IAV and experienced similar 
levels of morbidity (i.e., temperature loss), regardless of the hormonal milieu of the donor 
transferred CD8+ T cells treatment (Fig 3.6C; p < 0.05). Testosterone treatment of recipient mice 
accelerated the contraction of total numbers of leukocytes (i.e., CD45+ cells), eosinophils, CD8+ T 
cells, and WSN-Ova1 H1N1-specific CD8+ T cell relative to testosterone-depleted recipient male 
mice at 14dpi (Fig 3.6D-6G; p < 0.05), regardless of the hormonal environment of the donor 
transferred CD8+ T cells. Moreover, the contraction of adoptively transferred CD90.1+ CD8+ T 
cells producing IFNγ in response to ex vivo Ova-specific peptide stimulation was accelerated in 
testosterone-treated recipient mice at 14 dpi (Fig 3.6H; p < 0.05) relative to testosterone- 
depleted recipient mice, irrespective of the donor mouse treatment. These data demonstrate 
that testosterone creates a local environment that promotes accelerated contraction of virus-






Inflammatory immune responses, including cytokine production and activity of virus-specific 
CD8+ T cells, are required to control IAV infection, but if improperly regulated can contribute to 
tissue damage and severe outcomes [267, 268, 274, 444]. In the current and previous studies 
[164, 432], androgens, including testosterone and dihydrotestosterone, in male mice reduces 
the severity of IAV infection by promoting the resolution of pulmonary inflammation rather than 
by affecting viral replication. The improved resolution of IAV-induced inflammation [432] in 
androgen-treated males was not cause by suppression of the cytokine storm, but rather by 
mitigation of pulmonary CD8+ T cells after virus was cleared. The effect of androgens on the 
resolution of CD8+ T cell activity was dependent on androgen receptor signaling in the lungs, 
which indirectly reduced CD8+ T cell numbers and activity in the lungs following clearance of IAV.   
We and others [164, 302, 432] have shown that males experience less severe disease and 
recover faster from IAV than females. Data from the current study and others [302, 432] 
illustrate that testosterone limits pulmonary inflammation during IAV infection. In addition to 
reduced inflammation, males also repair damaged tissue faster than females which is mediated 
by greater production of epidermal growth factor amphiregulin in males than females [302]. 
Testosterone does not regulate production of amphiregulin; thus, elevated levels of both 
testosterone and amphiregulin contribute to improved IAV outcomes in males than females.   
In the current study, the depletion of testosterone resulted in the accumulation of 
eosinophils in the lungs following control of viral replication, which was unexpected given the 
lack of observed changes in pulmonary concentrations of IL-5, IL-13, and eotaxin. Eosinophils are 
androgen responsive despite the absence of androgen receptor expression [24, 54, 83], with 
testosterone-mediated differences in eosinophilic airway responses instead being attributed to 
the actions Type II innate lymphoid cells (ILC2s) [88, 89]. Though not evaluated in this study, 
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androgens have shown to inhibit the maturation ILC2s, while decreasing IL-5 production and 
eosinophilic responses in murine models of airway inflammation [88, 89]. Although the precise 
role of eosinophils in the immune response to IAV are unclear, previous studies in mice show 
accumulation of eosinophils in the lungs following control of viral replication [445, 446]. 
Whether the accumulation of eosinophils during the resolution phase of infection represents 
the activation of type 2 tissue repair responses [447], or a pathological response contributing to 
immunopathology warrants further study. 
In response to other inflammatory diseases, including experimental autoimmune 
encephalomyelitis, testosterone is associated with an expansion of Th2 and Th17 cell 
populations and suppression of Th1 activity [120, 122, 448]. During IAV pathogenesis, 
testosterone treatment of males did not lead to shifts in the differentiation of CD4+ T helper cell 
population. Furthermore, although testosterone treatment can promote the expansion in 
numbers and activation of Treg cells in murine models of inflammation [122-124], there was 
only a transient effect of testosterone on Treg cells during IAV infection. Whether this 
represents differences in the polarizing effects of infection versus other inflammatory states 
should be considered.   
During IAV infection, CD8+ T cells play a critical role in the control of IAV infection through 
the production of cytokines and the removal virus-infected cells [449]. Improper regulation or 
prolonged activation of virus-specific CD8+ T cell responses, however, can also cause 
immunopathology and severe pulmonary tissue damage [275, 277]. Both in humans and mice, 
testosterone alters the numbers, cytokine production, and proliferative potential of CD8+ T cells 
[91, 113]. Consistent with these observations, androgens, including testosterone, accelerated 
the contraction of virus-specific CD8+ T cells in the lungs, but not in the spleen or mediastinal 
lymph nodes. The significance of this tissue specific effect is unknown, but whether these effects 
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of testosterone on virus-specific CD8+ T cells involve activation-induced cell death or inhibitory 
pathways warrants future study.  
Testosterone can be metabolized by aromatase into estradiol to signal through estrogen 
receptor α, which can dampen inflammation and improve the outcome of IAV infection in 
females [164, 418, 439, 440]. Moreover, in male mice gonadectomized prior to the onset of 
puberty, castration-mediated protection against lethal IAV infection is reversed by testosterone 
treatment and subsequent conversion to estradiol, but not by treatment with non-aromatizable 
DHT [450]. In the present study, the protective effects of testosterone on IAV pathogenesis were 
dependent on androgen receptor signaling in the lungs. The discordant findings about the 
impact of androgens on IAV pathogenesis in prepubertal versus adult mice likely represent 
differences in developmental maturity.  
The dependence on androgen receptor signaling for accelerated contraction of virus-specific 
CD8+ T cells and the expression of Ar in enriched splenic CD8+ T cell populations suggested that 
testosterone might be acting directly on these CD8+ T cell to mitigate IAV pathogenesis. 
Adoptive transfer studies were conducted and revealed that the presence of testosterone in the 
recipient mice was a better predictor of IAV outcome and contraction of virus-specific CD8+ T 
cells than the presence of testosterone in the donor mice. These data suggest that testosterone 
is not acting directly on virus-specific CD8+ T cells to induce intrinsic changes in these cells via 
androgen signaling. Instead, testosterone induces transient changes in these cells that are 
dependent on the presence of testosterone in the local environment in which they reside. Given 
the widespread expression of androgen receptors both in immune cells and epithelial cells in the 
lung [54, 451], testosterone may be acting indirectly on virus-specific CD8+ T cells, through 
interactions with other cells to promote their contraction. One such cell type may be 
eosinophils, which accumulated in the lungs of testosterone-depleted males in our model, and 
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have recently been shown to promote the proliferation and activation of CD8+ T cells following 
IAV infection in murine models of allergic asthma [217].  
The impact of testosterone on infectious disease outcomes involves many cell types and 
responses. While our work has shown testosterone-induced changes in immune function to be 
protective, these same immunological changes can be detrimental in other instances, including 
with amoebic infection, in which treatment with testosterone increases the severity of infection 
at least in part through inhibition of IFNγ production by natural killer T cells [114, 143, 154]. 
When disease following infection is caused by the inability to control the pathogen, then 
androgens, like testosterone, are detrimental. Conversely, when disease following infection is 
largely attributable to immunopathology [54, 267], the immunomodulatory effects of 
testosterone are likely protective. These data suggest that testosterone confers protection 
during IAV infection by modulating the immune response and suggest that testosterone may 
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Figure and table legends 
Fig. 3.1. Testosterone depletion increases the severity of influenza A virus (IAV) infection. 
Adult male mice were gonadectomized and implanted with either testosterone (gdx + T) or 
placebo (gdx) containing capsules or received sham surgeries (intact) prior to inoculation with a 
sub-lethal dose of ma2009 H1N1 IAV. Plasma and seminal vesicles were collected at 21 days 
post inoculation (dpi) and testosterone concentrations (A) were analyzed by ELISA, while 
seminal vesical mass as a percentage of total body mass was calculated as a biomarker of 
androgenic activity (B; n = 11-12/treatment). Mice (n = 13-15/treatment) were monitored daily 
for changes in body mass (C), body temperature (D), and clinical disease severity (E). Infectious 
virus was measured in the lungs by TCID50 at 3, 7, and 14 dpi (F; n = 6-9/treatment/time-point). 
Data represent means +/- SEM from two independent replications and significant differences 
between treatment groups are denoted by asterisks (*p < 0.05).  
 
Fig. 3.2. Testosterone does not alter pulmonary cytokine or chemokine concentration during 
influenza A virus (IAV) infection. Adult male mice were gonadectomized and implanted with 
either testosterone (gdx + T) or placebo (gdx) containing capsules, and then inoculated with a 
sub-lethal dose of ma2009 H1N1 IAV or were mock infected. At 0, 3, 9, or 14 dpi (n = 8-
11/treatment/time-point), lung tissue was collected and homogenized, and cell free 
supernatants were used to quantify pulmonary concentrations of IL-6 (A), IL-12p40 (B), G-CSF 
(C), IFNγ (D), CCL2 (E) and IL-10 (F). Data represent means +/- SEM from two independent 
replications. No differences were seen between treatment groups.   
 
Fig. 3.3 Testosterone treatment reduces numbers of eosinophils and activity of virus-specific 
CD8+ T cells following control of viral replication. Adult male mice were gonadectomized and 
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implanted with either testosterone (gdx + T) or placebo (gdx) containing capsules, and then 
inoculated with a sub-lethal dose of ma2009 H1N1 IAV or mock infected. At select days post 
inoculation (dpi), mice were euthanized, and pulmonary immune cells were quantified by flow 
cytometry (n = 6-14/treatment/time-point). Surface marker and intracellular staining was used 
to identify numbers of CD45+ cells (A), eosinophils (B), total CD8+ T cells (C), ma2009 H1N1-
specific CD8+ T cells (D), CD8+ T cells producing IFNγ (E) in response to ex vivo H1N1-specific 
peptide stimulation, and poly-functional CD8+ T cells expressing both CD107a and IFNγ (F)  
following ex vivo H1N1-specific peptide stimulation (E). Data represent means +/- SEM from two 
independent replications and significant differences between treatment groups are denoted by 
asterisks (*p < 0.05).  
 
Fig. 3.4. The androgen receptor antagonist, flutamide, inhibits the protective effects of 
testosterone treatment on influenza A virus (IAV) pathogenesis. Adult male mice were 
gonadectomized and implanted with capsules containing placebo (gdx), testosterone (gdx + T), 
or flutamide + testosterone (flutamide + T), and seminal vesicle mass was quantified as the 
percentage of total body mass (A; n = 9/treatment). Following intranasal inoculation with a sub-
lethal dose of ma2009 H1N1 IAV, mice were monitored daily for changes in body mass (B) and 
body temperature (C) for 21 days post inoculation (dpi; n = 12-15/treatment). At 14- and 21-dpi, 
the total numbers of CD8+ T cells (D), H1N1-specific CD8+ T cell numbers (E), and the number of 
CD8+ T cells producing IFNγ in response to ex vivo H1N1-specific peptide stimulation (F) were 
quantified by flow cytometry (n = 8-10/treatment/time-point). Data represent means +/- SEM 
from two independent replications and significant differences between treatment groups are 




Fig. 3.5. The non-aromatizable androgen, dihydrotestosterone (DHT) mimics the protective 
effects of testosterone on influenza A virus (IAV) pathogenesis. Adult male mice were 
gonadectomized and implanted with capsules containing testosterone (gdx + T), DHT (gdx + 
DHT), or placebo (gdx), and seminal vesical mass was quantified as the percentage of total body 
mass (A; n = 6-8/treatment). Following intranasal inoculation with a sub-lethal dose of ma2009 
H1N1 IAV, mice were monitored daily for changes in body mass (B) and body temperature (C) 
for 21 days post inoculation (dpi; n = 13-15/treatment). At 14 and 21 dpi, the total numbers of 
CD8+ T cells (D), H1N1-specific CD8+ T cell numbers (E), and the number of CD8+ T cells producing 
IFNγ in response to ex vivo H1N1-specific peptide stimulation (F) were quantified by flow 
cytometry (n = 8-12/treatment/time-point). Data represent means +/- SEM from two 
independent replications and significant differences between treatment groups are denoted by 
asterisks (*p < 0.05).  
 
Fig. 3.6. Testosterone acts indirectly to promote the contraction of CD8+ T cell populations 
following control of viral replication. Adult male TCR-Ova mice were gonadectomized and 
implanted with capsules containing testosterone or placebo prior to infection with a sub-lethal 
dose of WSN-Ova1 H1N1 IAV (n = 5/treatment group). At 14 days post inoculation (dpi), mice 
were euthanized, CD8+ T cells were isolated by negative selection, and splenic mRNA was 
measured and normalized to GAPDH using the ∆CT method (A). Adoptive transfer experiments 
were preformed, and adult male TCR-Ova and CD90.1 mice were gonadectomized and 
implanted with capsules containing either placebo (gdx) or testosterone (gdx + T). Splenic CD8+ T 
cells were isolated from placebo- or testosterone-treated donor TCR-Ova mice by negative 
selection purification, and adoptively transferred by tail vein injection into either placebo- or 
testosterone-treated male CD90.1 recipient mice. Mice were then infected by intranasal 
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inoculation with a sub-lethal dose of WSN-Ova1 H1N1 IAV, and seminal vesicle mass was 
quantified as the percentage of total body mass (B; n = 6-7/treatment). Mice were monitored 
daily for changes in body temperature (C). At 14 dpi, mice were euthanized, and lung tissue was 
collected to quantify the numbers of CD45+ cells (D), eosinophils (E), total CD8+ T cells (F), Ova-
specific CD8+ T cells (G), and adoptively transferred CD90.2+ CD8+ T cells producing IFNγ in 
responses to OVA-specific peptide stimulation (H) were quantified by flow cytometry (n = 6-
7/treatment). Data represent means +/- SEM from two independent replications and significant 
differences between treatment groups are denoted by asterisks (*p < 0.05).  
 
Table 3.1. Total numbers of pulmonary myeloid cells following IAV infection in 
gonadectomized mice treated with placebo (gdx) or testosterone (gdx + T). Data are presented 
as the mean +/- SEM from 2 independent experiments (n = 8-10/treatment/timepoint) and 
significant differences between treatment groups are bolded and denoted by asterisks (*P < 
0.05). 
 
Table 3.2. Total numbers of pulmonary CD4+ T cells following IAV infection in gonadectomized 
mice treated with placebo (gdx) or testosterone (gdx + T). Data are presented as the mean +/- 
SEM from 2 independent experiments (n = 6-12/treatment/timepoint) and significant 
differences between treatment groups are bolded and denoted by asterisks (*P < 0.05). 
 
Table 3.3. Total numbers of CD8+ T cells in the mediastinal lymph nodes and spleens of 
gonadectomized mice treated with placebo (gdx) or testosterone (gdx + T) following IAV 




Supporting Table 3.1. Pulmonary cytokine and chemokine concentrations (pg/ml) following 
IAV infection in gonadectomized mice treated with placebo (gdx) or testosterone (gdx + T). 
Data are presented as the mean +/- SEM from 2 independent experiments (n = 8-
11/treatment/timepoint) and significant differences between treatment groups for each 














































































































Irradiated Sporozoite Vaccination Induces Sex-Specific Immune 
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Adult females tend to develop greater adaptive immune responses than males following receipt 
of either viral or bacterial vaccines, in both preclinical animal studies and human clinical trials. 
While there is currently no approved malaria vaccine, several anti-sporozoite vaccines, including 
RTS,S/AS01 and attenuated sporozoite vaccines, are in development, but the impact of sex or 
age on their efficacy remains undefined. To examine sex differences in the efficacy of anti-
sporozoite stage malaria vaccination, adult (10 weeks of age) or juvenile (11 days of age) male 
and female C3H mice were twice vaccinated with irradiated transgenic Plasmodium berghei 
sporozoites expressing the P. falciparum circumsporozoite (CSP) protein and 45 days post boost 
vaccination mice were challenged with transgenic P. berghei via mosquito bite or intradermal 
challenge. Immunization with irradiated sporozoites resulted in greater protection against 
challenge in adult females, which was associated with greater anti-CSP antibody production and 
avidity, as well as greater hepatic, but not splenic, CD8+ T cell IFNƴ production in adult females 
relative to adult males. No sex differences in adaptive immune responses or protection were 
observed in mice vaccinated prior to puberty, suggesting a role for sex steroid hormones. 
Depletion of testosterone in males increased, whereas rescue of testosterone decreased, anti-
CSP antibody production, the number of antigen-specific CD8+ T cells isolated from the liver, and 
protection following parasite challenge. Conversely, depletion of sex hormones in female mice 
did not alter vaccine response or protection following challenge. These data suggest that 
elevated testosterone concentrations in males reduce adaptive immunity and contribute to sex 







Malaria is a significant global burden of disease worldwide, with most cases occurring in 
sub-Saharan Africa. In 2017, malaria was estimated to result in 216 million clinical cases and 
445,000 deaths [332]. Worldwide, malaria causes approximately 5% of all deaths in children 
under 5 years of age, primarily due to Plasmodium falciparum in sub-Saharan Africa [333]. In 
response, the World Health Organization (WHO) has set out a strategy to achieve a 90% 
reduction in malaria cases and mortality by the year 2030 [336]. Current methods to interrupt 
malaria transmission, however, including the early diagnosis and treatment of cases, vector 
control (e.g., insecticide treated bed net use and residual indoor insecticide spraying), 
prophylactic drug treatment, and healthcare capacity improvements, are economically costly 
and unlikely to achieve these goals on their own [337]. To complement these approaches, the 
need for a malaria vaccine that is at least 75% protective has been identified and would likely be 
the most cost-effective method for controlling malaria [337, 342]. 
The RTS,S/AS01 vaccine is currently the leading candidate malaria vaccine undergoing 
pilot implementation in several regions of sub-Saharan Africa [342]. The RTS,S/AS01 vaccine 
targets the pre-erythrocytic stage of the malarial life-cycle and consists of the carboxy-terminal 
region of the P. falciparum circumsporozoite (CSP) surface protein along with the hepatitis B 
surface antigen. In Phase III clinical trials, the RTS,S/AS01 vaccine was shown to be moderately 
efficacious with 18-36% protection against clinical disease in young boys and girls (i.e., ages 6-12 
weeks and 5-17 months) [350]. The RTS,S/AS01 vaccine, however, was also associated with 
higher all-cause mortality in girls, but not in boys, in both age groups in which the vaccine was 
tested [393]. Though significant, the mechanisms underlying this sex-differential outcome 
remain unclear, but these observations highlight the potential for sex-specific differences in the 
outcomes of malaria vaccination [452]. While no other malaria candidate vaccine has reached 
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Phase III clinical trials, other candidate vaccines, including several whole sporozoite vaccines, are 
currently undergoing preliminary clinical trials [343]. Regardless of the candidate vaccine, to 
date, clinical trials have been conducted solely in healthy adult volunteers or children without 
consideration of the influence of sex as a biological variable [453]. 
Clinical data illustrate that in both children and adults, males and females can differ in 
vaccine-induced immune responses and protection [166]. Following vaccination, juvenile and to 
a greater extent adult females often develop higher antibody responses, generate more robust 
cell-mediated immunity, and are better protected by vaccination, but also experience more 
frequent and severe adverse reactions than age matched males [165, 166, 454]. The 
mechanisms mediating these vaccine-associated differences are incompletely understood, but 
have been attributed to the effects of sex steroid signaling, sex chromosome complement, 
epigenetic regulation, and the microbiome on immune responses to vaccine antigens [166]. Less 
well known is the influence that the route of administration, vaccine composition (e.g. live 
attenuated versus inactivated), dose, and pathogen type may have on sex differences in vaccine-
induced immune responses. Our current knowledge of the influence of sex on vaccination has 
generally been informed by vaccines targeting viruses and bacteria [165, 166], with little clinical 
data pertaining to vaccines against parasitic infections, including malaria.  
Preclinical animal models have proven useful for studying vaccine efficacy and the 
immune response to malaria [455]. But here to, little consideration has been given to sex as a 
biological variable, with most studies either not reporting the sex of the animals or only using 
female animals [456-459]. In murine studies of malaria blood stage infection, females have 
reduced mortality, experience faster resolution of infection associated anemia and weight loss, 
and mount a more robust immune response to infection (e.g. increased IFNƴ, IL-10, and 
plasmodium specific IgG1 antibody production) than males [380]. Consistent with these 
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observations, females are better protected against challenge than males following vaccination 
with the surface membranes of P. chabaudi infected red blood cells [168]. To date, no pre-
clinical study has been adequately designed or analyzed to study sex differences in the 
immunogenicity and efficacy of pre-erythrocytic stage malaria vaccination. In this study, we 
examined the influence of sex, age, and sex hormones on the efficacy and immune response to 





















Materials and Methods 
Mice 
All animal procedures were approved by the Johns Hopkins Animal Care and Use Committee 
(M016H35). Adult (8-10 weeks old) male and female C3H/HeNCr MTV mice were purchased 
from Charles River (Wilmington, MA) and housed at 5 animals per microisolator cage. For 
studies using juvenile mice, time pregnant (arrived at embryonic day 12) female C3H/HeNCr 
MTV mice were purchased from Charles River (Wilmington, MA) and housed as individual dams 
with pups until weaning. Pups were weaned at post-natal day (PND) 21, separated by sex, and 
housed at 3-5 animals per microisolator cage. All mice were housed under standard BSL-2 
housing conditions and given food and water ad libitum. 
 
Irradiated sporozoite vaccination 
Previously generated transgenic P. berghei sporozoites expressing the immunodominant P. 
falciparum circumsporozoite (CSP) protein (P.b.-P.f.) were used for all vaccinations [357]. For 
studies in adult mice, mice were twice vaccinated at 14-day intervals by tail vein injection with 1 
x 105 sporozoites gamma irradiated at a dose of 25gy using Cs-137 as the source (GammaCell 
1000). Due to the body size and inaccuracy of accessing the tail vein, juvenile mice were twice 
vaccinated by intraperitoneal injection at 14-day intervals beginning at PND 11 with 1 x 105 
gamma irradiated P.b.-P.f. sporozoites.  
 
Anti-circumsporozoite protein enzyme-linked immunosorbent assays (ELISA) 
ELISA plates (Greiner Bio-One) were coated with 100μl per well of purified recombinant CSP 
peptide [357] diluted in 1X Phosphate buffered Saline (PBS, Gibco) at a concentration 1μg/ml. 
After incubation overnight at room temperature (RT), plates were washed three times with 
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200μl of PBS, before blocking with 200μl PBS-BSA (1X PBS with 1% BSA, Sigma) for 2 hours at RT. 
Following three washes with PBS, serially diluted plasma samples were added, and incubated at 
RT for 1 hour. The plates were washed two times with PBS-Tween (1X PBS with 0.5% Tween20, 
Sigma) followed by two washes with PBS and 100μl of secondary antibody (IgG; KPL, IgG1; 
ThermoScientific, or IgG2a; Invitrogen) at a 1:1000 dilution was added for 1 hour at RT. Plates 
were then washed three times with PBS-Tween followed by three times with PBS and 100μl of 
horseradish peroxidase substrate (KPL) was added to each well and developed in the dark for 
15minutes. The reaction was stopped using 50μl of 1% SDS (Fisher) and the plates were read at 
405nm. Antibody titers were calculated as the highest plasma dilution with an optical density 
(OD) value greater than three times the average OD of the negative controls. Titer curves were 
plotted after normalization to the negative control and the area under the titer curve (AUC) was 
calculated and the dilution titer equal to an optical density of 1 (OD1) was determined by non-
linear regression. For semiquantitative assessment of antibody concentration, a titer curve was 
generated using known quantities of the P. falciparum CSP specific monoclonal antibody 2A10 
[460], with a concentration of 400μg/ml assigned a value of 1000 ELISA Units (EU). Non-linear 
regression was then used to generate an equation for the reference antibody curve and the OD 
values for each experimental sample were interpolated into the reference antibody equation to 
determine the relative concentration in EUs. For all calculations, only the linear portion of the 
curve was used and resulting concentrations were multiplied by the dilution factor to obtain the 
final relative antibody concentration for each experimental sample.  
 
Anti-circumsporozoite (CSP) avidity assay 
ELISA plates were coated with of 100μl per well of purified CSP peptide [357] diluted in PBS at a 
concentration 1μg/ml. After incubation overnight at RT, plates were washed three times with 
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200μl of PBS, before being blocked with 200μl PBS-BSA for 2hrs at RT. Following three washes 
with 200μl PBS, plasma samples were plated in quadruplicate at a 1:200 dilution in PBS-BSA and 
incubated for 1 hour at room temperature. Plates were washed two times with 200μl PBS-
Tween followed by two washes with PBS. To measure antibody avidity, 2M ammonium 
thiocyanate (NH4SCN; Sigma) or PBS was added to the plates for exactly 15 minutes. The plates 
were washed two times with PBS-Tween followed by two times with PBS and peroxidase- 
labeled goat anti-mouse IgG antibody was added at a concentration of 500ng/ml and incubated 
for 1 hour at RT. Plates were washed three times with PBS-Tween followed by three times with 
PBS and 100μl of horseradish peroxidase substrate was added to each well and developed in the 
dark for 15minutes. The reaction was stopped using 50μl of 1% SDS and the plates were read at 
405nm. The antibody avidity index was determined by dividing the NH4SCN treated optical 
density values by the corresponding PBS (untreated) values for each sample in duplicate.  
 
Sporozoite challenge 
Mice were sedated with Ketamine-Xylazine and challenged by mosquito bite using 10 P.b.-P.f. 
infected female Anopheles stephensi mosquitoes or challenged by intradermal injection with 3 x 
103 chimeric P.b.-P.f. CSP sporozoites 45 days after the boost vaccination. Hepatic parasite loads 
were quantified forty-two hours post-challenge by RT-qPCR targeting P. berghei 18s rRNA using 
forward primer 5’ -TGGGAGATTGGTTTTGACGTTTATGT- 3’ and reverse primer 5’ -
AAGCATTAAATAAAGCGAATACATCCTTAC-3’ as described previously [461]. Resulting parasite 
loads were expressed as P. berghei 18s rRNA copy number as well as the log and percent 





CD8+ T cell responses 
Single cells suspensions were generated by homogenizing tissue through a 100μm nylon filter 
(Falcon) followed by ACK lysis of red blood cells (Quality biologicals) for splenic tissue or Percoll 
gradient separation (GE) for hepatic tissue. The total numbers of live cells for both splenic and 
hepatic samples were determined using a hemocytometer and trypan blue (Invitrogen) 
exclusion, and cells were resuspended at 40 × 106 cells/ml in RPMI 1640 (Cellgro) supplemented 
with 10% fetal bovine serum (Fisher Scientific), 1% L-glutamine (Gibco), and 1% penicillin-
streptomycin (Gibco). Isolated cells were plated out at 2 x 106 cells/well and incubated for 5-
6hrs at 37°C with 5 x 105 cells/well of either peptide pulsed (DYENDIEKKI – 10ug/10 x 106 cells) 
or non-pulsed LM1 cells at in the presence of GolgiPlug (BD) and GolgiStop (BD). Following 
incubation, Fc receptors were blocked using anti-CD16/32 (BD Biosciences) and cells were 
stained with CD8-PerCPCy5.5 (Clone 53-6.7; BD). Cells were then permeabilized and fixed (BD 
Cytofix/Cytoperm) prior to intracellular staining with IFNƴ -FITC (Clone XMG1.2; BD) and TNFa-
PE (Clone MP6-XT22; BD). Data were acquired using a FACSCailubr flow cytometer (BD) running 
Cell Quest Pro and analyzed using FlowJo (v.10) software (Tree Star, Inc.).  
 
Gonadectomy and hormone replacement  
Adult male and female mice (9-10 weeks) were bilaterally gonadectomized (gdx) or sham 
surgeries were performed with the mice remaining gonadally intact as previously described 
[164]. For males, two weeks following gonadectomy, mice were implanted subcutaneously with 
silastic tubing capsules (inner diameter-0.04", outer diameter- 0.085"; HelixMark) containing 
crystalline testosterone propionate (gdx + T; 10.0 mm; Sigma) of left empty (gdx) [433]. The 
capsules were sealed with 2.5 mm of medical adhesive (Factor II, A-100), and incubated at 37°C 
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overnight in sterile saline solution prior to implantation. Capsules were replaced prior to 
depletion every 28 days for the duration of the study. 
 
Sex-hormone enzyme immunosorbent assays 
Plasma was collected 3 days prior to challenge and total testosterone, or estradiol 
concentrations were quantified by commercial EIA kits according to the manufacturer’s 
instructions (IBL America – testosterone; Calbiotech – estradiol). To prevent sample 
degradation, care was taken to limit light and thermal exposure of plasma samples prior to 
hormone quantification.   
 
Statistical analysis 
Data were analyzed by Mann-Whitney U test or Kruskal-Wallis test followed by Dunn’s test for 
pairwise multiple comparisons. Statistical analyses were performed using GraphPad Prism 7.05 














Adult female mice mount greater antibody responses to irradiated sporozoite vaccination 
 To test if the sexes respond differently to malaria vaccination, we used an established 
model where adult male and female C3H mice were twice vaccinated with 1 x 105 irradiated 
P.b.-P.f. sporozoites by intravenous injection [462]. Forty-two days post boost vaccination, anti-
CSP IgG titers were significantly greater in adult females than males (Mann-Whitney, P < 0.05; 
Fig. 4.1A). To confirm these findings, anti-CSP IgG data were further analyzed for the area under 
the curve (AUC), the titer equal to an optical density-1 (OD1), and antibody quantity. Regardless 
of the method used to quantitatively measure anti-CSP IgG antibody responses, adult females 
exhibited greater responses following vaccination than adult males (Mann-Whitney, P < 0.05 in 
each case; Fig. 4.1B-D).  
In addition to antibody quantity, qualitative differences in humoral responses can 
influence vaccine efficacy. To assess the impact of sex on qualitative antibody traits following 
irradiated sporozoite vaccination, antibody avidity, which is associated with protection from 
sporozoite challenge [457], was measured. Anti-CSP antibody avidity was significantly greater in 
adult female compared to adult male mice (Mann-Whitney, P < 0.05; Fig. 4.1E). Because avidity 
can be influenced by antibody isotype and IgG1, but not IgG2a/c, titers are associated with 
sterile immunity against P. berghei [457], we evaluated sex differences in IgG isotypes. Overall, 
females had significantly greater anti-CSP IgG1 and IgG2a antibody titers than males (Mann-
Whitney, P < 0.05 in each case; Fig. 4.1F and Fig. 4.1G). The IgG1:IgG2a ratio, however, was 
similar between the sexes (Mann-Whitney, Fig. 4.1H), suggesting that no sex-specific shift in 
Th2/Th1 skewing was apparent. Taken together, these data suggest that the quality and 
quantity of antibody following receipt of an irradiated sporozoite vaccine is greater in adult 
female than male mice.  
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Adult female mice have increased numbers of antigen-specific hepatic CD8+ T cells and 
are better protected following parasite challenge 
 To evaluate sex differences in irradiated sporozoite vaccine efficacy, adult male and 
female mice were challenged by mosquito bite using 10 P.b.-P.f. infected female mosquitoes 45 
days post boost vaccination. Forty-two hours after challenge, hepatic and splenic CD8+ T cells 
were isolated and the number of cells producing IFNƴ in response to CSP-specific peptide 
stimulation was quantified. Following CSP peptide stimulation, the number of hepatic CD8+ T 
cells producing IFNƴ was significantly greater in adult females than males (Mann-Whitney, P < 
0.05; Fig. 4.2A). In contrast, while peptide stimulation increased production of IFNƴ by splenic 
CD8+ T cells in vaccinated mice, no sex differences were observed (Mann-Whitney, P < 0.05 for 
peptide stimulation; Fig. 4.2B). To assess whether sex differences in immune responses to the 
vaccine resulted in differential vaccine efficacy, we measured hepatic P. berghei 18s rRNA copy 
number as a surrogate for parasite load 42 hours post challenge. Parasite load was lower in 
vaccinated mice relative to naïve mice of both sexes; mean parasite load among vaccinated 
adult females, however, was significantly lower relative to adult males (Kruskal-Wallis, P < 0.05; 
Fig 4.2C). To determine whether sex differences in parasite load were reflective of differential 
mosquito bite numbers, and hence exposure, the number of blood fed mosquitoes (i.e. those 
with visible midgut blood content) was recorded for each mouse. Though the number challenge 
mosquito bites varied among individual mice, no sex differences in mosquito bite numbers were 
observed in either vaccinated or naïve mice (Kruskal-Wallis; Fig 4.2D). 
Because of the variation in mosquito bite numbers, and presumably challenge dose, 
challenge experiments were repeated using intradermal inoculation with 3 x 103 P.b.-P.f. 
sporozoites at 45 days post boost vaccination. Consistent with mosquito bite challenge, 
vaccinated mice had greater numbers of IFNƴ + CD8+ T cells in the liver and spleen following ex 
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vivo peptide simulation (Mann-Whitney, P < 0.05 in each case; Fig. 4.2E and Fig. 4.2F). Following 
CSP-specific peptide stimulation, numbers of CD8+ T cells producing IFNƴ in the liver, but not the 
spleen, were greater in vaccinated female than male mice following intradermal challenge 
(Mann-Whitney, P < 0.05 for hepatic CD8+ T cells and P > for splenic CD8+ T cells; Fig. 4.2E and 
Fig. 4.2F). Also, consistent with mosquito bite challenge, hepatic P. berghei 18s rRNA copy 
number was significantly reduced in both sexes following vaccination, with the magnitude of the 
reduction being greater in adult females than males (Kruskal-Wallis, P < 0.05; Fig 4.2G). As 
another way to analyze the change in parasite load following vaccination, we calculated the log 
reduction in parasite load relative to the average parasite load in naïve mice for each sex and 
experimental replication. Consistent with the relative parasite load (Fig 4.2G), as compared with 
naïve mice, the log reduction in parasite load was greater for vaccinated females than males 
(Mann-Whitney, P > 0.05; Fig. 4.2H). In summary, these data demonstrate that irradiated 
sporozoite vaccine efficacy is greater in adult females than in male mice.  
 
Prior to puberty, vaccine responses and efficacy do not differ between the sex 
Sex differences in the immune responses to vaccines are often not evaluated in studies 
of childhood vaccines [166], but there are some vaccines, including the RTS,S vaccine, that are 
primarily or exclusively administered prior to puberty [342, 463]. To characterize the impact of 
sex on irradiated sporozoite vaccine response and efficacy prior to puberty, juvenile mice were 
twice vaccinated by intraperitoneal injection beginning at postnatal day (PND) 11. Forty-two 
days post boost vaccination, antibody responses were analyzed by measuring anti-CSP IgG titers, 
AUC, the OD1 titer, and antibody quantity. Although vaccination resulted in detectable antibody 
responses against CSP, no sex differences in any measure of the antibody response to CSP were 
detected among mice vaccinated as juveniles (Mann-Whitney, P > 0.05; Fig. 4.3A and Suppl. Fig. 
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4.1). The avidity of anti-CSP IgG also did not differ between males and female vaccinated as 
juveniles (Mann-Whitney, P > 0.05; Fig. 4.3B). Finally, the titers of anti-CSP IgG1 and IgG2a were 
quantified and neither titers of IgG isotypes nor the ratio of IgG1:IgG2a differed between sexes 
among mice vaccinated as juveniles (Mann-Whitney, P > 0.05; Fig. 4.3C-E).  
As adults, mice that were vaccinated with irradiated sporozoites as juveniles received an 
intradermal challenge with transgenic P.b.-P.f. parasites. Unlike mice that were both vaccinated 
and challenged as adults, among mice vaccinated as juveniles and challenged as adults there 
was no significant increase in the number of hepatic or splenic CD8+ T cells producing IFNƴ in 
response to CSP specific peptide stimulation, which also did not differ between the sexes 
(Kruskal-Wallis, P > 0.05; Fig. 4.3F and Fig. 4.3G). Although juvenile vaccination was efficacious, 
there was no sex difference in the log reduction in parasite load (Mann-Whitney; Fig. 4.3H). 
Taken together, these data suggest vaccination prior to puberty does not result in sex 
differences in vaccine efficacy, suggesting that sex steroid hormones may be involved.  
 
Removal of ovaries has no effect on vaccine-induced immune responses or protection 
among adult females  
 To begin to test whether sex hormones in females contribute to greater vaccine-induced 
immune responses and protection, a subset of females had their ovaries removed thereby 
reducing concentrations of 17β-estradiol (Mann-Whitney, P < 0.05 Fig. 4.4A). Removal of the 
ovaries in adult female mice, however, did not significantly alter either the quality or quantity of 
anti-CSP IgG at 42 days post boost vaccination as compared with gonad-intact (i.e., sham) 
female mice (Mann-Whitney, P > 0.05; Fig. 4.4B-E and Suppl. Fig. 4.2). Following sporozoite 
challenge, while peptide stimulation increased production of IFNƴ by both splenic and hepatic 
CD8+ T cells from vaccinated mice, gonadectomy increased CSP-specific splenic, but not hepatic, 
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CD8+ T cell production of IFNƴ following peptide stimulation (Kruskal-Wallis, P < 0.05 for splenic 
CD8+ T cells and P > 0.05 for hepatic CD8+ T cells; Fig. 4.4F and Fig. 4.4G). Finally, the log 
reduction in hepatic parasite load following intradermal challenge did not differ between intact 
or gonadectomized female mice (Mann-Whitney, P > 0.05; Fig. 4.4H). Taken together these data 
suggest that immunity and protection from parasite challenge in female mice may be 
independent of female gonadal sex hormones.  
 
Testosterone suppresses vaccine-induced immune responses and protection in male 
mice 
 To determine whether testosterone in males affected irradiated sporozoite vaccine 
responses, adult male mice underwent sham surgeries or gonadectomy, with half the 
gonadectomized males receiving endogenous testosterone, which increased circulating 
testosterone to within the physiological range of gonad-intact males (Kruskal-Wallis, P < 0.05; 
Fig. 4.5A). Following vaccination, depletion of testosterone significantly increased, whereas 
rescue of testosterone significantly decreased, anti-CSP IgG antibody titers and avidity as well as 
anti-CSP IgG1 antibody titers (Kruskal-Wallis, P < 0.05; Fig. 4.5B-F and Suppl. Fig. 4.3). Rescue of 
testosterone significantly reduced IgG2a antibody titers and the ratio of IgG1:IgG2a relative to 
testosterone-depleted males (Kruskal-Wallis; Fig. 4.5E and Fig. 4.5F).  
Following intradermal challenge, the depletion of testosterone significantly increased 
the number of hepatic CD8+ T cells producing IFNƴ in response to CSP-specific peptide 
stimulation, while the rescue of testosterone levels reduced hepatic CD8+ T cell production of 
IFNƴ to a level comparable with gonad-intact male mice (Kruskal-Wallis, P < 0.05; Fig. 4.5G). 
Depletion of testosterone also significantly increased the log reduction in parasite load, whereas 
the rescue of testosterone significantly reduced the log reduction in parasite load as compared 
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with naïve mice from the same hormone treatment group (Kruskal-Wallis, P < 0.05; Fig. 4.5H). 
Taken together, these data suggest that the decreased efficacy of irradiated sporozoite 
























Sex differences in vaccine-induced immune responses are documented primarily for 
vaccines that protect against viruses and bacteria [57, 166], with considerably less attention 
paid to parasitic vaccines, including those that could protect against malaria. In the present 
study, following irradiated sporozoite vaccination, adult female mice were better protected 
against sporozoite challenge than age-matched males, with these differences in protection 
being associated with greater adaptive immune responses, including malaria-specific antibody 
and CD8+ T cell responses in females compared with males. These findings are consistent with 
both human and murine studies showing greater immunogenicity and efficacy of erythrocytic 
stage malaria vaccination in adult females relative to males [168, 348], as well as in murine 
models of Plasmodium infection [380]. Sex differences in sporozoite vaccine-induced immunity 
and protection were not observed among mice that were vaccinated prior to puberty. The surge 
of testosterone during puberty in males as opposed to hormonal changes following puberty in 
females appeared to be a critical mediator of sex differences in vaccine-induced immunity and 
protection in adults.  Manipulation of sex steroid hormones (i.e., estradiol and progesterone) in 
females had no impact on vaccine-induced immunity and protection, whereas manipulation of 
testosterone in males dramatically affected the outcome of vaccination. 
Malaria vaccination programs will largely target infants and children as these groups 
suffer the greatest burden of disease from malaria [333, 342, 463]. Sex differences have been 
described for some infant and childhood vaccines, with females generally, but not always, 
mounting greater antibody responses to vaccination [166]. In the current study, males and 
females that were vaccinated as juveniles had similar CSP-specific antibody and CD8+ T cell 
responses as well as protection against challenge infection.  We did not compare vaccine-
induced immune responses and protection between adults and juveniles because while adult 
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mice were vaccinated via intravenous inoculation of irradiated sporozoites, this route of 
vaccination was not feasible in juvenile mice due to the small size of their tail vein contributing 
to technical inaccuracies. For juvenile mice, intraperitoneal inoculations were used, which has 
been shown to be less efficacious for whole sporozoite vaccination [464]. Because the route of 
vaccination differed between adult and juvenile mice, it is not possible to conclude that the 
vaccine was less efficacious in juvenile than adult mice, only that the sex difference in vaccine-
induced immunity was present in adult, but not juvenile, mice. We cannot, however, rule out 
that the route of vaccination may impact sex differences in vaccine-induced immunity. 
The observation that sex influences the immunogenicity and efficacy of irradiated 
sporozoite vaccination in adults, but not in mice vaccinated as juveniles, led us to hypothesize 
that changes in sex hormone concentrations associated with puberty may be involved. At 
puberty, the ovaries of females begin synthesizing and releasing elevated concentrations of 
estradiol and progesterone, whereas the testes of males begin synthesizing greater 
concentrations of testosterone. These sex steroid hormones affect adaptive immune responses 
both directly by binding to sex steroid receptors on B and T cells as well as indirectly by altering 
the activity of innate immune cells [130, 465].  
In females, estradiol, in particular, can enhance antibody responses to vaccines and 
infections [56, 166, 380, 466, 467]. In murine models of malaria blood stage infection, treatment 
of female mice with estradiol alone or in combination with progesterone increased Plasmodium-
specific IgG1 antibody production as well as IFNƴ production by splenocytes relative to sex-
hormone depleted females [466]. Treatment of female mice with other forms of estrogen, e.g., 
estriol, or progesterone stimulates antibody responses to influenza virus antigens, whereas 
progesterone suppresses memory CD8+ T cell formation, at least in response to a primary 
infection [431, 467, 468]. In the current study, depletion of sex steroids in females did not alter 
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either the adaptive immune response to vaccination or protection following parasite challenge. 
Whether these discordant effects of female sex hormone depletion represent differences in the 
context of vaccination versus infection, the route of inoculation, or differences in the pathways 
of immune activation warrant future study. Moreover, there may be other sex-specific factors 
(e.g., genetic or epigenetic factors) that could be contributing to the more robust immune 
response in adult females relative to adult males.  
The immunosuppressive properties of testosterone are well characterized, but few 
studies have evaluated the impacts of testosterone on the immune response to vaccination. 
Notably, in humans, elevated serum concentrations are associated with reduced humoral 
responses to the trivalent inactivated influenza vaccine [104]. To determine if testosterone 
suppressed the immune response to irradiated sporozoite vaccination in males, testosterone 
concentrations were depleted by castration and replaced in castrated males with exogenous 
continuous-release capsules that increased testosterone to within physiological range of adult 
males. Depletion of testosterone in males increased, whereas the testosterone treatment of 
castrated males decreased, parasite load following sporozoite challenge. These findings agree 
with previous murine studies demonstrating that testosterone suppresses resistance to blood 
stage infection and reduces protection against challenge following erythrocytic stage 
vaccination [168, 390]. Moreover, immunity against Plasmodium sporozoite infection has been 
shown to be dependent on high concentrations of anti-CSP antibodies and CSP-specific CD8+ T 
cells [469, 470]. Consistent with these observations, testosterone depletion increased, while 
testosterone treatment decreased, the magnitude of the CSP-specific antibody response and 
number of CSP-specific CD8+ T cells isolated from the liver as revealed by IFNƴ production 
following CSP-specific peptide stimulation. In addition to altering the quantity of vaccine 
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induced antibody produced, testosterone altered the quality of antibody produced in response 
to vaccination.  
Anti-CSP IgG1 antibodies, which are associated with a Th2 cellular responses and 
parallel antibody avidity, play and important role in sterile immunity against sporozoite 
challenge [457, 471]. In the current study, depletion of testosterone increased IgG1, but not Th1 
associated IgG2a, titers relative to testosterone-replete males, resulting in a skewing of the anti-
sporozoite IgG1/IgG2a ratio. Whether testosterone induced changes in CD4+ T helper cell 
polarization was not evaluated but should be considered in future studies. The precise 
mechanisms by which testosterone affects antibody and T cell responses to vaccination remains 
to be determined, and future study of testosterone signaling in B cells and T cells is warranted.  
Most pre-clinical malaria vaccine studies use exclusively female mice or do not consider the sex 
of the animals used [456]. In this study, we demonstrate that testosterone in males is a 
significant factor mediating sex differences in the immunogenicity and efficacy of a preclinical, 
pre-erythrocytic malaria vaccine design. Greater consideration of biological sex and sex-specific 
factors are needed in the experimental design and analysis of preclinical animal studies as well 
as clinical trials of malaria vaccines. Though testosterone is unlikely to influence the outcomes of 
childhood malaria vaccination, understanding the mechanisms by which testosterone 
suppresses vaccine efficacy may provide insight leading to improvements in malaria vaccine 
design. 
Most pre-clinical malaria vaccine studies use exclusively female mice or do not consider 
the sex of the animals used [456]. In this study, we demonstrate that testosterone in males is a 
significant factor mediating sex differences in the immunogenicity and efficacy of a preclinical, 
pre-erythrocytic malaria vaccine design. Greater consideration of biological sex and sex-specific 
factors are needed in the experimental design and analysis of preclinical animal studies as well 
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as clinical trials of malaria vaccines. Though testosterone is unlikely to influence the outcomes of 
childhood malaria vaccination, understanding the mechanisms by which testosterone 
suppresses vaccine efficacy may provide insight leading to improvements in malaria vaccine 
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Fig. 4.1. Effects of sex on antibody responses to irradiated sporozoite vaccination. Adult (8-10 
weeks) male and female mice were twice vaccinated with irradiated sporozoites at 14-day 
intervals. Forty-two days post boost vaccination, plasma was collected and anti-CSP IgG titers 
(A), areas under the curve (AUC) (B), anti-CSP titers equal to an optical density-1 (C), anti-CSP 
antibody concentrations (D), anti-CSP antibody avidity (E), anti-CSP IgG1 titers (F), anti-CSP 
IgG2a titers (G), and the ratio of IgG1/IgG2a (H) were measured. Data represent means +/- the 
SEM from two independent replications (n = 34-39/sex) and significant differences are denoted 
with asterisks (*P < 0.05).  
 
Fig. 4.2. Effects of sex on CD8+ T cell responses and protection from sporozoite challenge. Naïve 
and irradiated sporozoite vaccinated adult (8-10 weeks) male and female mice were challenged 
by mosquito bite 45 days post boost vaccination. The numbers of hepatic (n = 3 pools of 
3/sex/treatment) (A) and splenic (n = 16-18/sex/treatment) (B) CD8+ T cells producing IFNƴ in 
response to CSP-specific peptide stimulation were measured 42 hours post challenge. Hepatic P. 
berghei 18s rRNA copy number (C) was measured (n = 9-15/sex/treatment) in naïve and 
vaccinated male and female mice. The number of blood fed mosquitos was recorded for each 
challenge (n = 18-20 mice/sex/treatment) (D). Challenge experiments were repeated with 
intradermal inoculation, and the numbers of hepatic (n = 6 pools of 3/sex/treatment) (E) and 
splenic (n = 16-18/sex/treatment) (F) CD8+ T cells producing IFNƴ in response to CSP peptide 
stimulation were measured 42 hours post challenge. Hepatic P. berghei 18s rRNA copy number 
was measured (n = 15/sex/treatment) (G) and the log reduction (H) in parasite load relative to 
naïve controls was determined (n = 15/sex). Data represent means +/- the SEM from two 
independent replications and significant differences are denoted with asterisks (*P < 0.05). 
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Fig. 4.3. Effects of sex on vaccine-induced immunity and protection in juvenile mice. Pre-
pubertal (2 weeks of age) male and female mice were twice vaccinated with irradiated 
sporozoites. Forty-two days post boost vaccination, plasma was collected and anti-CSP IgG 
concentrations (A), anti-CSP antibody avidity (B), anti-CSP IgG1 titers (C), anti-CSP IgG2a titers 
(D), and the ratio of IgG1/IgG2a (E) were measured (n = 15-18/sex). Naïve and vaccinated 
juvenile mice were challenged as adults by intradermal inoculation 45 days post boost 
vaccination and the numbers of hepatic (n = 4-5 pools of 3/sex) (F) and splenic (n = 11-14/sex) 
(G) CD8+ T cells producing IFNƴ in response to CSP peptide stimulation were measured 42 hours 
post challenge. The log reduction (H) in parasite load relative to naïve controls was determined 
(n = 9-12/sex). Data represents means +/- SEM from two independent replications. No 
differences by sex were observed in mice vaccinated as juveniles.  
 
Fig. 4.4. Effects of ovariectomy on irradiated sporozoite vaccination in adult female mice. Adult 
(8-10 weeks) female mice were assigned to remain intact (i.e., receive a sham surgery) or be 
ovariectomized (ovx) two weeks prior to being twice vaccinated with irradiated sporozoites. 
Plasma was collected 42 days post boost vaccination and estrogen (A) (n = 8-9/treatment), anti-
CSP IgG antibody concentrations (B), anti-CSP antibody avidity (C), anti-CSP IgG1 titers (D), and 
anti-CSP IgG2a titers (E) were measured (n = 15-18/ treatment). Mice were challenged by 
intradermal inoculation and the numbers of hepatic (n = 4 pools of 3/treatment) (F) and splenic 
(n = 9-10/treatment) (G) CD8+ T cells producing IFNƴ in response to CSP-specific peptide 
stimulation were quantified. The log reduction in parasite load was measured (n = 9-
10/treatment) (H) relative to naïve female mice. Data represent means +/- SEM from two 
independent replications and significant differences between treatment groups are denoted by 
asterisks (*P < 0.05). 
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Fig. 4.5. Effects of testosterone on irradiated sporozoite vaccination in adult males. Adult (8-10 
weeks) male mice were gonadectomized and implanted with placebo (gdx) or testosterone (gdx 
+ T) capsules or received sham surgeries (sham). Mice were twice vaccinated with irradiated 
sporozoites and 42 days post boost vaccination, plasma was collected and testosterone 
concentrations (A) were quantified (n = 8-9/treatment). Anti-CSP IgG antibody concentrations 
(B), anti-CSP antibody avidity (C), anti-CSP IgG1 titers (D), anti-CSP IgG2a titers (E), and the ratio 
of IgG1/IgG2a titers were measured (n = 18-29/ treatment group). Mice were challenged by 
intradermal inoculation and the numbers of hepatic (n = 4-8 pools of 3/treatment) (G) CD8+ T 
cells producing IFNƴ in response to CSP-specific peptide stimulation were quantified. The log 
reduction in parasite load (n = 8-15/treatment) (H) relative to naïve male mice was measured 42 
hours post challenge. Data represents means +/- SEM from two independent replications and 
significant differences across treatment groups are denoted by asterisks (*P < 0.05). 
 
Supplemental Fig. 4.1. Juvenile mice were twice vaccinated with irradiated sporozoites 
beginning at postnatal day 11. Forty-two days post boost vaccination, plasma was collected and 
anti-CSP IgG titers (A), areas under the curve (AUC) (B), and the anti-CSP IgG titers equal to an 
optical density-1 were measured (n = 16-18/sex). Data represents means +/- SEM from two 
independent replications. No differences by sex were observed in juvenile mice. 
 
Supplemental Fig. 4.2. Adult (8-10 weeks) female mice were ovariectomized (ovx) or received 
sham surgeries (sham) and mice were twice vaccinated with irradiated sporozoites. Plasma was 
collected 42 days post boost vaccination and anti-CSP IgG titers (A), areas under the curve (AUC) 
(B), and the anti-CSP IgG titers equal to an optical density-1 were measured (n = 16-
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19/treatment). Data represents means +/- SEM from two independent replications. No 
differences by treatment group were observed. 
 
Supplemental Fig. 4.3. Adult (8-10 weeks) male mice were gonadectomized and implanted with 
placebo (gdx) or testosterone (gdx + T) capsules or received sham surgeries (sham). Mice were 
twice vaccinated with irradiated sporozoites and 42 days post boost vaccination, plasma was 
collected and anti-CSP IgG titers (A), areas under the curve (AUC) (B), and the anti-CSP IgG titers 
equal to an optical density-1 were measured (n = 17-28/treatment). Data represents means +/- 
SEM from two independent replications and significant differences across treatment groups are 

































































































































































The research within this dissertation illustrates the need for a better understanding of 
how testosterone influences of the outcomes of infection and vaccination. Moreover, the 
findings of this dissertation demonstrate a novel role for testosterone in both reducing the 
severity of IAV infection males while inhibiting protective immunity to pre-erythrocytic stage 
malaria vaccination. These finding may have applications to other disease models and may 
provide novel insights leading to new infectious disease interventions and improvements in 
malaria vaccine design.  
 
Testosterone confers protection against IAV mediated disease 
 Improperly regulated or persistent inflammatory responses can contribute to severe 
disease during IAV [267, 268, 274, 444]. In chapter 2, I made the unique observation that in 
hypogonadal males, whether age-related or surgically induced, testosterone treatment reduces 
the severity of IAV infection. Moreover, testosterone replacement in aged males reduced 
mortality following IAV infection. These effects were most pronounced during the recovery 
phase of infection (i.e., after virus had been cleared), and were associated with the delayed 
resolution of pulmonary inflammation, rather than changes in viral replication. These 
observations were expanded in chapter 3, where I showed that the delayed resolution of 
pulmonary inflammation and disease in testosterone depleted males was associated with the 
persistence of viral-specific CD8+ T cells and the influx of eosinophils into lungs following control 
of viral replication. This is consistent with the literature which demonstrates an 
immunoregulatory role of testosterone [5, 23, 54-57]. As highlighted in the introductory 
chapter, the immune suppressive role of testosterone may be advantageous to overall male 
health as demonstrated the association of hypogonadism with increased all-cause mortality [35, 
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40-43]. The data contained within this dissertation suggest that testosterone replacement 
therapy may have additional benefits in the context of infectious disease.  
 
Testosterone and not estrogen mediate sex differences following irradiated sporozoite 
vaccination  
In the current study, depletion of female sex steroids did not alter either the adaptive 
immune response to vaccination or protection following parasite challenge. This is discordant 
with published literature showing both estradiol and progesterone to alter humoral immune 
responses and memory CD8+ T cell formation [56, 166, 380, 431, 466-468]. Whether these 
differences in the effects of female sex hormone depletion represent differences in the context 
of vaccination versus infection, the route of inoculation, or differences in the pathways of 
immune activation warrant future study. Given that female mice were inherently more 
protected than males independent of female sex-hormone status, elucidation of the 
contributions other sex-specific factors (e.g., X-linked gene dosage) play in contributing to the 
more robust immune response in adult females relative to adult males warrants future study. As 
a notable example, several genes with immune function (e.g., CD40lg) identified as being 
associated with hepatic, but not splenic, memory CD8+ T cell responses to irradiated sporozoite 
vaccination, are expressed on the X chromosome [472]. As adult females mounted greater 
hepatic, but not splenic CSP-specific CD8+ T cell responses to irradiated sporozoite vaccination, 
whether the expression of these genes in females lymphocytes is greater due to escape from X 
chromosome inactivation should be considered [473].  
In contrast with females, depletion of testosterone in males increased, whereas rescue 
of testosterone decreased, adaptive immune responses and protection in males following 
parasite challenge. Though the immunosuppressive properties of testosterone are 
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characterized, the impact of testosterone on vaccine responses has rarely been considered. 
Notably, in humans, elevated serum concentrations are associated with reduced humoral 
responses to the trivalent inactivated influenza vaccine [104]. Furthermore, as any malaria 
vaccination program will largely target pre-pubertal cohorts (i.e., infants and children), the 
suppressive effects of testosterone on pre-erythrocytic stage malaria vaccination may be largely 
inconsequential. Instead I propose, that understanding the mechanisms by which testosterone 
suppresses pre-erythrocytic stage vaccine efficacy will allow us to better inform malaria vaccine 
design. If we can identify the pathways that restrict vaccine efficacy, we can potentially exploit 
those pathways to enhance malaria vaccine efficacy. Moreover, future studies evaluating sex 
differences in RTS,S/ASO1 vaccine response and efficacy should be considered. 
 
Testosterone replacement in aged males reduces mortality following IAV infection  
In aged males, testosterone replacement reduced mortality and clinical severity, but had 
minimal effects on either morbidity or pulmonary inflammation. It is possible that increased 
survival in testosterone-treated aged males created a bias towards animals that were severely 
ill, but otherwise survived, masking differences between treatment groups during recovery from 
pulmonary inflammation at later time points during infection. Alternatively, other age-related 
physiologic changes may render the aged population more refractory to testosterone’s 
protective effects. Consistent with this hypothesis, studies of androgen-dependent regulation of 
angiogenesis, found aging to be associated with reduced androgen responsiveness due to 
defective androgen receptor nuclear translocation in response to treatment [415]. Whether age-
related defects in androgen signaling reduces the efficacy to testosterone treatment in our 
models warrants future consideration. Aging is also associated with profound dysregulation of 
the immune response to IAV, including delayed induction of both the innate and adaptive arms 
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of the immune system [474-477]. Given the effects of testosterone were most pronounced 
during the resolution phase of infection in young males, independent of changes in viral 
replication, it is possible that testosterone may not be able to resolve the issues of delayed 
immune induction in aged mice. Characterization of the effects of testosterone on the immune 
response to IAV in aged male will aid in elucidating the mechanisms by which testosterone 
reduces age-associated increases in mortality, but otherwise has minimal effects on morbidity 
and pulmonary inflammation.  
 
Testosterone mitigates the accumulation of pulmonary eosinophils following IAV 
infection  
Following control of IAV replication, the depletion of testosterone resulted in the 
accumulation of eosinophils in the lungs, which could not be explained by testosterone-
associated changes in pulmonary concentrations of the type 2 cytokine (e.g., IL-5, IL-13, and 
eotaxin). Interestingly, previous studies in mice have also shown an accumulation of eosinophils 
in the lungs following control of IAV replication [445, 446], in the absence of detectable 
increases in IL-5 [446]. Although the precise role of eosinophils in the immune response to IAV 
are unclear, it has been suggested that that the accumulation of these cells represents the 
activation of type 2 tissue repair responses mediated by the production of the epidermal growth 
factor amphiregulin [446, 447]. Discordant with this hypothesis, our lab has previously reported, 
that though males are dependent on amphiregulin to repair damaged lung tissue faster than 
females, testosterone does not regulate the production of amphiregulin in response to IAV 
infection [302]. This would indicate that eosinophils may instead be contributing to 
immunopathology (e.g., eosinophilic pneumonia). Supporting this hypothesis, eosinophils have 
recently been shown to promote the proliferation and activation of CD8+ T cells following IAV 
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infection in murine models of allergic asthma [217]. Furthermore, virus-specific CD8+ T cells, 
which contribute to IAV-associated immunopathology [232, 277], also persisted in the lungs of 
testosterone-depleted mice in conjunction with eosinophilic infiltration.  
Eosinophils are androgen responsive despite the absence of androgen receptor 
expression [24, 54, 83], with testosterone-mediated differences in eosinophilic airway responses 
instead being attributed to the actions Type II innate lymphoid cells (ILC2s) [88, 89]. Though not 
evaluated in this study, androgens have been shown to inhibit the maturation of ILC2s, while 
decreasing IL-5 production and eosinophilic responses in murine models of airway inflammation 
[88, 89]. Additional work to determine if testosterone is acting on ILC2 cells to inhibit 
eosinophilic following control influenza viral replication may have implications for other airway 
inflammatory diseases. Further, whether CD8+ T cell cytotoxicity induced alarmin release is 
driving the eosinophilic response, as has recently been shown in a study of concanavalin A-
induced hepatitis [478], should be considered. 
Testosterone has also been shown to be protective against eosinophil associated 
inflammation in murine models of asthma and upper-airway inflammation [89, 438]. As 
mentioned above, testosterone reduces eosinophilic upper-airway inflammation by suppressing 
ILC2 numbers and their production of IL-5 and IL-13, by inducing intrinsic changes in these cells 
and through reductions in the expression of IL-33 and TSLP [89]. Additionally, testosterone 
suppresses house dust mite-induced eosinophilic inflammation and airway hyperresponsiveness 
through the suppression of IL-17A+  Th17 cell numbers and their relative production of IL-23R 
mRNA [438]. In vitro, supraphysiological concentrations of testosterone (i.e., 50ng/ml but not 
5ng/ml) reduce eosinophil viability and adhesion to human mucosal microvascular endothelial 
cells (HMMEC) through an unknown mechanism [87, 479]. Whether, testosterone ameliorates 
lower-airway eosinophil associated diseases (e.g., eosinophilic pneumonia and chronic 
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obstructive pulmonary disease), and non-airway eosinophilic associated diseases (e.g., atopic 
dermatitis, eosinophilic esophagitis, and eosinophilic colitis) has not been evaluated [480-482].  
 
Testosterone does not alter the CD4+ T cell response to IAV infection  
Though the depletion of testosterone in male mice promoted the accelerated 
contraction of total CD4+ T cell numbers, in response to testosterone, no differences in the 
numbers of Th1, Th2, or Th17 cells were observed as compared to placebo treated mice. In 
other inflammatory diseases, including experimental autoimmune encephalomyelitis, 
testosterone is associated with an expansion of Th2 and Th17 cell populations while suppressing 
Th1 activity [120, 122, 448]. Whether this represents differences between the strongly Th1-
polarizing effects of IAV infection versus other inflammatory states should be considered. An 
alternate hypothesis is that single peptide stimulation of CD4+ T cell in flow cytometry may not 
be adequate to capture the breadth of the protein-specific response of these individual cell 
types. The best way to further characterize polarization of CD4+ T cells would be cytokine 
capture ELISpot analyses using virus-specific synthetic peptide pools as described by DiPiazza et 
al. [218, 483]. Additionally, regulatory T cells were increased at 21 days following IAV infection in 
testosterone-depleted males relative to testosterone replete male mice. This conflicts with 
testosterone treatment being demonstrated to promote the expansion in numbers and 
activation of regulatory T cells in murine models of inflammation [122-124]. This difference may 
be attributed to the greater pulmonary damage observed in testosterone depleted males, rather 





Testosterone promotes the contraction of CD8+ T cells following control of IAV 
infection 
The reduced severity of disease and pulmonary inflammation in testosterone-treated 
males following IAV infection was paralleled with the accelerated contraction of virus-specific 
CD8+ T cells in the lungs, but not the spleen or mediastinal lymph nodes following control of viral 
replication. This observation is consistent with both the critical role IAV-specific CD8+ T Cells play 
in controlling viral replication [231, 275, 276, 449], as well as their contribution to pulmonary 
immunopathology with prolonged or improperly regulated activation [232, 275, 277]. Both in 
humans and mice, testosterone alters the numbers, cytokine production, and proliferative 
potential of CD8+ T cells [91, 113]. The significance of this tissue-specific effect is unknown, but 
whether these effects of testosterone on virus-specific CD8+ T cells involve activation-induced 
cell death or inhibitory pathways warrants future study.  
The dependence on androgen receptor signaling for accelerated contraction of virus-
specific CD8+ T cells and the expression of Ar in enriched splenic CD8+ T cell populations 
suggested that testosterone might be acting directly on these CD8+ T cell to mitigate IAV 
pathogenesis. Adoptive transfer studies were conducted and revealed that the presence of 
testosterone in the recipient mice was a better predictor of IAV outcome and contraction of 
virus-specific CD8+ T cells than the presence of testosterone in the donor mice. These data 
suggest that testosterone is not acting directly on virus-specific CD8+ T cells to induce intrinsic 
changes in these cells via androgen signaling. Instead, testosterone induces transient changes in 
these cells that are dependent on the presence of testosterone in the local environment in 
which they reside. Given the widespread expression of androgen receptors both in immune cells 
and epithelial cells in the lung [54, 451], testosterone may be acting indirectly on virus-specific 
CD8+ T cells, through interactions with other cells to promote their contraction. If testosterone 
146 
 
in acting indirectly on CD8+ T cells, then characterization of androgen receptor expression in the 
pulmonary environment during IAV infection may help identify potential interacting cell types. 
One such cell type may be eosinophils, which accumulated in the lungs of testosterone-depleted 
males in our model, and have recently been shown to promote the proliferation and activation 
of CD8+ T cells following IAV infection in murine models of allergic asthma [217]. The use CD8+ T 
cell lineage specific androgen receptor knock-out mice may be a better approach to further 
characterize whether testosterone is acting directly or indirectly to accelerate IAV-specific CD8+ 
T cell contraction. 
 
Testosterone exerts tissues-specific effects on antigen-specific CD8+ T cells 
 In both Chapters 3 and 4, tissue-specific effects of testosterone on antigen specific CD8+ 
T cell populations were observed, with testosterone promoting the contraction of virus-specific 
CD8+ T cells in the lungs, but not in the in the spleen or mediastinal lymph nodes, following IAV 
infection, while testosterone reduced the numbers of CSP-specific CD8+ T cells in the liver, but 
not spleen, following irradiated sporozoite vaccination. Though novel for CD8+ T cells, these 
observations are consistent with previous reports of tissue-specific effects of testosterone on 
histamine production by mast cells in animal models, with testosterone depletion increasing 
histamine concentrations in the peritoneum, but not the lungs [484]. Moreover, testosterone 
and DHT have been demonstrated to have differential effects on vascular vasorelaxation based 
on localization within the host [485], suggesting that testosterone is able to exert regional 
effects within the same tissue type as well. Though the factors mediating these differences in 
androgenic effects are unclear, tissue-specific differences in testosterone concentration have 
been described in animal models [486, 487], with these differences at least in part being 
mediated by tissue-specific differences in the ability to uptake SHBG and albumin-bound 
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testosterone [488]. To date no murine studies have evaluated tissue-specific testosterone 
concentrations in the lungs or lymphatic system outside of the testes, and no studies have 
compared relative testosterone concentrations between the spleen and liver. Whether, the 
observed tissue specific effects of testosterone on CD8+ T cells populations are mediated by 
local differences in testosterone concentration warrants future consideration. Furthermore, 
whether tissue specific interactions alter androgen receptor or androgen receptor-coregulator 
expression by CD8+ T cells is also unknown but may provide an alternate mechanism explaining 
tissue specific effects of testosterone.   
  Though not explored in these studies, it is also possible that the observed tissue-specific 
effects of testosterone on CD8+ T cell populations may be due to testosterone mediated changes 
in the expression of factors involved with the migration to, and persistence within, specific sites 
of infection and inflammation. For example, LFA-1/ICAM-1 interactions have been identified as 
critical to the retention of activated lymphocytes in the lungs [489, 490], while P-selectin 
glycoprotein ligand 1 (PSGL-1) is an adhesion molecular involved in the recruitment of CD8+ T 
cells to the lungs in addition to playing a role in promoting T cells homeostasis [491-493]. 
Similarly, CCR5 and CXCR6 expression by T cells are required for the maintenance of memory 
liver antigen-specific T cells [494, 495], while ICAM-1 and VCAM-1 have been identified to play in 
role in the retention of T cells in the liver [496]. Though the effects of sex and sex hormones on T 
cell migration and adhesion molecule expression remains largely uncharacterized, observations 
that estrogen can inhibit PSGL-1 expression [497] and testosterone can modify TNFα mediated 
VCAM-1 expression by endothelial cells [498, 499], suggest that this may be an area warranting 
future study. Of specific interest would be sphingosine-1-phosphate and its receptors, which in 
addition to being involved in the trafficking of activated CD8+ T cells to the liver in the context of 
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malaria [500], have recently been shown to be androgen responsive in other model systems 
[501, 502].  
 
Testosterone and humoral immunity 
The effects of testosterone on antibody responses to either infection or vaccination 
have rarely been considered, but where evaluated, testosterone has been reported to 
suppressive humoral immunity. Notably, in humans, neutralizing antibody production in 
response to influenza vaccination is inversely correlated with serum testosterone concentration 
[104], while testosterone treatment of human PBMCs reduces production of non-specific total 
IgG and IgM antibodies [92]. In contrast with these reports, in the influenza experiments 
detailed in Chapter 2, the manipulation of testosterone had no effect on either neutralizing or 
virus specific IgG titers following infection with the PR8 H1N1 influenza virus. As these findings 
were unexpected, these experiments were repeated using the ma2009 H1N1 influenza virus, 
and again both neutralizing and virus specific IgG titers were not altered with testosterone 
treatment. Whether these discordant findings reflect differences in androgen signaling between 
humans and mice, systemic immunization versus local pulmonary infection, or differences in the 
immunogen construct are unclear. However, in the experiments detailed in Chapter 4, the 
manipulation of testosterone had profound effects on anti-CSP specific total IgG and IgG1 titers 
following irradiated sporozoite vaccination. To date, no studies have evaluated the effects 
testosterone on memory B cell responses. Whether testosterone has differential effects on 
plasma B cells generated in response to acute primary infection versus the maintenance and 




Does testosterone act through dendritic or CD4+ T cell populations to suppress 
irradiated sporozoite vaccine efficacy? 
The suppression of both CSP-specific humoral and CSP-specific CD8+ T cell responses by 
testosterone following irradiated sporozoite vaccination, suggest the possibility of a shared 
pathway in mediating these effects, with the actions of CD4+ T cells and dendritic cells being two 
possible avenues. Antigen-specific CD4+ T cells are important for the adequate priming and full 
development of CD8+ T effector cell populations [503-506], in addition to being crucial for the 
survival and secondary expansion of memory CD8+ T cell populations [504, 507-511]. CD4+ T cell 
subsets also support the generation and maintenance of long lived plasma cells along with 
memory B cells [512-514], while cytokine production by CD4+ T cells induces antibody class 
switching [515], and regulatory T cells have been shown to suppress productive interactions 
between Tfh and B cells during malarial blood stage infection [516]. Moreover, at least In rodent 
models, cytotoxic Th1 like CD4+ T cells have been identified that are capable of directly 
controlling malaria liver stage infection through the removal of infection hepatocytes [514, 517, 
518]. Similarly, antigen presenting dendritic cell subsets are also involved in the generation of 
both humoral and CD8+ T cell responses to pre-erythrocytic malaria responses; often in 
conjunction or upstream of CD4+ T cell responses. Notably, CD8a+ and CD11c+ dendritic cell 
populations contribute to CD8+ T cell priming and activation [500, 511, 519, 520], while dendritic 
cells contribute to antibody mediated protection through the direct presentation of antigen to B 
cells in addition to the induction of the above mentioned CD4+ T cell help [521, 522]. Any 
potential role for testosterone in altering dendritic or CD4+ T cell responses to irradiated 
sporozoite vaccination were not evaluated in this dissertation. However, despite testosterone 
not acting through either population in the context of IAV infection, data from other disease 
model systems, as summarized in chapter 1, strongly suggest that testosterone can alter both 
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the proinflammatory and immunosuppressive responses of these two relatively diverse cell 
types. Furthermore, despite the potential implications on antibody mediated protection, to date 
no study has yet directly evaluated the effects of testosterone on Tfh cell populations. Whether 
testosterone is altering Tfh cell responses to irradiated sporozoite vaccination should be 
considered. 
 
Testosterone alters tolerance, but not resistance to IAV infection  
In response to microbial challenge, hosts can employ one of two distinct evolutionary 
strategies to ensure survival: tolerance and resistance [523-525]. Resistance to infection is 
traditionally defined as the ability of the host to kill or expel a pathogen or otherwise inhibit its 
reproductive success [523-525]. This strategy is dependent on the robustness of both the innate 
and adaptive immune response to the pathogen [526]. Because of the immune system’s efforts 
to eliminate the pathogen, substantial host tissue damage or loss of function can consequently 
occur [527-529]. Disease tolerance, however, reduces the fitness costs of infection independent 
of changes of pathogen survival or burden [526, 527]. Through tolerogenic responses, the 
consequences of either pathogen or immune-mediated damage can be ameliorated, 
subsequently maintaining host health [526-529]. Moreover, these strategies are not mutually 
exclusive, with many of the same immune system components contributing to both host 
resistance and tolerance [524, 525, 530]. For example, Th2-associated alternatively activated 
macrophages are involved in helminthic parasite killing, in addition to the repair of helminthic 
parasite-induced tissue damage [531].  
 In the context of IAV infection, testosterone did not alter resistance to infection as both 
testosterone-depleted and testosterone-replete males maintained similar viral replication 
kinetics. Testosterone instead improved tolerance of IAV infection (i.e., alleviated body mass 
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loss and hypothermia) through reductions in the numbers of pulmonary eosinophils and virus-
specific CD8+ T cells following control of viral replication. Thus, testosterone accelerated the 
resolution of pulmonary inflammation and reduced immunopathology in young males in the 
absence of immune alteration that interfered with control of viral replication. When advanced 
age was added as confounder, though aged males were slower to clear virus, no changes in viral 
replication were observed with testosterone treatment. However, in contrast with young males, 
testosterone failed to reduce body mass decline or hypothermia in aged males, while significant 
improvements in both survival and clinical severity were still observed. The data from these 
studies demonstrate that the protective effects of testosterone on IAV infection are mediated 
by improvements in host tolerance and resilience (i.e., the ability to recover from disease [532]), 
rather than through alterations to resistance type responses.  
 
The broader evolutionary impacts of testosterone on the immune response 
 Observations that testosterone both regulates male secondary sexual trait development 
in addition to suppressing the immune response has led to the development of the 
immunocompetence handicap hypothesis (ICHH) [533]. This hypothesis proposes that since 
testosterone imposes an immunological fitness cost, only high fitness or resistant (i.e., able to 
remain pathogen free) males can maintain energetically costly testosterone mediated secondary 
sexual traits in the presence of strong immunological pressure [533-535]. Moreover, when intra-
host resources are limited, lower fitness males will be unable to afford the energetic costs of 
maintaining immunocompetence simultaneously with those of testosterone mediated sexually 
selective traits. In support of this hypothesis, several studies using vertebrate animal models 
have demonstrated a correlation between reduced parasite load, or the ability to cope with high 
parasite loads, and the expression of testosterone mediated secondary sexual traits [536-538]. 
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Similarly, the data presented in this dissertation and by others, abundantly demonstrate that 
testosterone can suppress the immune response to both vaccination and infection [5, 23, 104, 
106, 121]. The individual consequences of this testosterone-mediated immune suppression are 
likely to depend on the nature and severity of the immunological challenge and the magnitude 
of sexual selection.  
The ICC hypothesis also proposes that the interactions between testosterone and the 
immune system are dynamic and bidirectional, with the temporary suppression of testosterone 
being an mechanism to overcome infection in the presence of sexual selection [533, 539]. 
Specifically under the pressure of substantial immunological challenge, the fitness costs imposed 
by the infection will overwhelm the fitness benefits of maintaining secondary sexual 
characteristics, resulting in a decline in circulating testosterone concentrations [533, 539]. In 
agreement with this hypothesis, In chapter 2, I demonstrate that IAV infection induces a 
transient decline in testosterone concentration in young male mice corresponding with the 
onset of disease, while no decline in the relatively lower testosterone concentrations were 
observed in aged male mice approaching reproductive senescence [432, 540]. These findings are 
consistent with the observations of others demonstrating that immune activation, irrespective 
of the source, can suppress endogenous testosterone production [539, 541-544].  
However, variation in the vertebrate immunological response to testosterone suggest 
that the evolutionary consequences of testosterone-immune interactions may be more 
complex. In contrast with the findings of Furman et. al., a recent report in young, affluent, and 
healthy males [5, 23, 106, 121], found no evidence in support of the assumptions of the ICC 
hypothesis following inactivated influenza vaccination, with free testosterone and DHT instead 
being positively correlated with the magnitude of antigen-specific IgG antibody responses at 4 
weeks post vaccination. Similarly, in avian populations, experimental treatment of captive bird 
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populations with testosterone has been observed to suppress antibody responses to 
immunization with sheep red blood cells (SRBC), while in free-living males, testosterone was 
positively correlated with the robustness of the antibody response to SRBC immunization [536]. 
These observations along with others, have led to the proposal of a multitude of  potential 
confounders and environmental interactions, including the nature of the immunological 
challenge, differences in vertebrate system biology, immune parameters measured, the 
condition of the host (e.g., age, reproductive status, presence of comorbidities), interactions 
with glucocorticoid stress hormones, and the potential conversion of testosterone to estrogen 
[534, 545-549]. Furthermore, it is likely that the expression of testosterone doesn’t incur a 
fitness cost under conditions of high resource availability and low competitive stress, where 
adequate intra-host resources allow for robust expression of simultaneous immunocompetence 
and secondary sexual characteristics. Whether the potential metabolic savings of testosterone 
mediated immune suppression would outweigh the metabolic costs of any resulting infection 
has also been challenged [550]. 
An alternate hypothesis is that rather than being broadly immunosuppressive, as 
assumed by the ICH hypothesis, testosterone instead acts to modify and/or redistribute 
components and responses of the immune system [550]. With this idea, testosterone selectively 
modulates individual components of the immune system, in response to host status and 
environmental stimuli. Furthermore, as with the ICH hypothesis, these interactions would be 
transient and bidirectional to maximize reproductive success. Consistent with this hypothesis, 
testosterone has been observed to enhance neutrophil and mast cells numbers and responses 
[551, 552], while promoting platelet aggregation [553-555]. It is worth noting, that for many 
species, testosterone promotes aggressive interactions and the potential for wounding, while 
simultaneously promoting immune system components (e.g., mast cells, neutrophils, and 
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platelet aggregation) involved in early responses to wounding [556-561]. In contrast, 
testosterone generally, but not always, suppresses B cell, Th2, and Th17 associated immunity, 
while reducing the NK cell activity and the production of proinflammatory mediators by 
macrophages [90, 561-564]. If testosterone has evolved a role of limiting the energetic cost of 
the immune system in favor of reproductive success, then the ability to selectively alter the 
immune system in response to specific stimuli would reduce the fitness costs associated with 
secondary sexual traits. In accordance with this idea, I did not observe testosterone to broadly 
suppress the immune response to IAV infection. Instead testosterone suppressed eosinophilic 
and virus-specific CD8+ T cell responses only following control of viral replication, while 
neutrophil numbers were transiently increased, and other immune parameters were not 
altered. Similarly, though testosterone suppressed both antibody and CSP-specific CD8+ T cell 
responses following irradiated sporozoite vaccination, it is possible that in the absence of 
previous exposure, the immunological challenge of an essentially killed vaccine, was insufficient 
to warrant energetic resource reallocation. Whether intra-cage social hierarchy continues to 
modify testosterone associated responses could provide additional insight into the relationships 
between testosterone and the evolution of sexual selection 
 
The impact of testosterone on infectious disease 
The relationships between testosterone and the outcomes of infectious disease appear 
to be complex. While in Chapter 2 and Chapter 3, I show testosterone-induced changes in 
immune function to be protective against severe disease following IAV infection, in other animal 
models of infection, testosterone has been shown to worsen disease outcomes. Notably in 
rodent models of amoebic infection [114, 143, 154], Babesia infection [155], Leishmania 
infection [157, 158], mycobacterium infection [160, 161], and with malaria [381, 385-389], 
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testosterone has been shown to increase infection severity in association with increased 
pathogen load. I hypothesize that when disease following infection is due the ability to control 
the pathogen, testosterone will likely be detrimental. Conversely, in infections where disease is 
largely attributable to the immune response to infection, as with sub-lethal IAV infections [54, 
267], the immunosuppressive effects of testosterone will likely be protective. To date, few 
clinical studies have evaluated the impact of testosterone on infections; including infection with 
IAV. Whether testosterone in males increases the risk of secondary infection in males, warrants 



















The overall impact of this dissertation resides in its novelty. Despite the increasing 
numbers of hypogonadal men, and the widespread use of testosterone replacement therapy, 
very little work has evaluated the effects of testosterone on the outcomes of infection. No 
studies to date have considered the effects of testosterone on the efficacy of pre-erythrocytic 
stage malaria vaccination. With this research, I hope to raise awareness of the potential impacts 
of testosterone on the outcomes of infection and vaccination. Although the exact mechanisms 
by which testosterone mediates these effects deserve to be further explored, understanding the 
mechanisms by which testosterone suppresses vaccine efficacy may provide insight leading to 
improvements in malaria vaccine design. Furthermore, these findings suggest that testosterone 
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